

RAJ S. PRUTHI MD, FACS
Curriculum Vitae

Education

- 1994-98 Stanford University, Stanford, California
Residency, Urology
- 1995-96 Stanford University, Stanford, California
Fellow, Prostate cancer and ultrasonography, Dept. of Urology
- 1993-94 Stanford University, Stanford, California
Residency, General Surgery
- 1992-93 Stanford University, Stanford, California
Internship, General Surgery
- 1988-92 Duke University School of Medicine, Durham, North Carolina
M.D., May, 1992
- 1984-88 Stanford University, Stanford, California
B.S. in Biology and B.A. in Economics with Honors, June, 1988

Board Certification/Licensure

- American Board of Urology 2002, recertification 2009
Louisiana State Board of Medical Examiners 1999
North Carolina Medical Board 1998
Drug Enforcement Agency 1993

Professional Experience

- 5/2011 – present Division of Urology, UNC School of Medicine, Chapel Hill, NC
Division Chief, Professor of Surgery
- 01/2011-05/2011 Division of Urology, UNC School of Medicine, Chapel Hill, NC
Division Chief, Associate Professor of Surgery
- 5/2006 – 01/2011 Division of Urology, UNC School of Medicine, Chapel Hill, NC
Associate Professor of Surgery (tenure)
- 4/2000 – 5/2006 Division of Urology, UNC School of Medicine, Chapel Hill, NC
Assistant Professor of Surgery
- 4/1999 – 4/2000 Dept. of Urology, LSU Medical Center, Shreveport, Louisiana
Assistant Professor of Urology
- 8/1998 – 4/1999 Kinston Urological Associates, Kinston, North Carolina
Private Practice of Urology

Honors/Awards

Faculty Teaching Award (“Attending of the Year), Division of Urologic Surgery, 2011-2012
Castle and Connolly’s Best Doctors in America 2010-2011
America’s Top Doctors for Cancer, 2010-2011
“Best Doctors in North Carolina”, 2010-2011
2009 Best Reviewer for Prostate Cancer Articles – Journal of Urology, May 2010
North Carolina Urology Seminar - Third Prize, Research, 2008
“Best Doctors in America”, 2003-04, 2004-2005, 2005-2006, 2006-2007, 2007-2008
Faculty Teaching Award (“Attending of the Year), Division of Urologic Surgery, 2006-07
“Best Doctors in North Carolina”, 2004-2005, 2005-2006, 2006-2007
North Carolina Urology Seminar - Second Prize, Research, 2006
North Carolina Urology Seminar - First Prize, Research 2005
North Carolina Urology Seminar - Second Prize, Case Report, 2005
North Carolina Urology Seminar – Third Prize, Case Report, 2004
North Carolina Urology Seminar – First Prize, Research, 2004
North Carolina Urology Seminar – Second Prize, Research, 2003
North Carolina Urology Seminar – Third Prize, Case Report, 2002
North Carolina Urology Seminar – First Prize, Research, 2002
Excellence in Teaching Award, University of North Carolina School of Medicine, 2002
Excellence in Teaching Award, University of North Carolina School of Medicine, 2001
T. Leon Howard Pyelogram Conference – Second Prize, SEUA Meeting, 2001
North Carolina Urology Seminar – Third Prize, Case Report, 2001
Faculty Teaching Award (“Attending of the Year”), Division of Urologic Surgery, 2000-01
Northern California Resident’s Competition -- First Prize, U.C.S.F., 1997
Northern California Resident’s Competition -- Second Prize, U.C. Davis, 1996
Northern California Resident’s Competition -- First Prize, Stanford University, 1995
Merck Book Prize, Duke University, 1992
Pathology Research Scholar Award, Duke University, 1990-1991
American Liver Foundation Research Scholarship, Duke University, 1990-1991
Thomas J. Watson Scholarship, Stanford University, 1984-1988
Jordan Scholar, Stanford University, 1984-1985

Bibliography

Book Chapters

Badrinath Konety, Willem Oosterlinck, Sam Chang, Sigurdur Gudjonsson, Raj Pruthi, Mark Soloway, Eduardo Solsona, Paul Sved. (2012) Low Grade Ta Urothelial Carcinoma of the Bladder. In M. Soloway, &S Khoury (Eds.), *Bladder Cancer* (2nd ed., pp. 233-246). Paris-France: Springer.

Pearson M., Pruthi R.S. Quality of Life in men undergoing radical prostatectomy for prostate cancer. In Handbook of Disease Burdens and Quality of Life Measures. V. Preedy (Ed.) 2010. Springer, New York, pp 2877-2885.

Ramirez M., Pruthi R.S., deVere-White R. Pelvic Lymphadenectomy. In Glenn’s Urologic Surgery (7th edition). Graham S. and Keane T. (Eds.) 2009. Lippincott Williams, pp 179-194.

Fielding J., Pruthi R.S. Imaging of nephrolithiasis, urinary tract infections and their complications. In Evidence-Based Imaging: Optimizing Imaging in Patient Care Medina, L. Santiago; Blackmore, C. Craig (Eds.) 2006. Springer, New York, pp 542-552.
In Press/Submitted

Manvar A, Pruthi RS, Wallen EM, Nielsen ME. Epidemiology. In The Textbook of Prostate Cancer. Ashutosh Tewari (ed). 2011. Springer.

Ferguson JE, Pruthi RS, Wallen EM, Nielsen ME. Racial Disparities and the Global Picture. In The Textbook of Prostate Cancer. Ashutosh Tewari (ed). 2011. Springer.

Smith A, Nielsen ME, Wallen EM, Pruthi RS. Patient Surveillance after Prostate Cancer Treatment. In Patient Surveillance After Cancer Treatment. Johnson F, Virgo K, Margenthaler J, et al (Eds.). 2011. Springer. 7 typed pages.

Nix J, Nielsen ME, Wallen EM, Pruthi RS. Robotic anterior exenteration in females: Technique, current status and outcomes. In Robotic in Genitourinary Surgery. Menon M and Hemal A. (Eds.) 2011. 9 typed pages.

Journal Articles (refereed)

1. Mmeje CO, Nunez-Nateras R, Nielsen ME, Pruthi RS, Smith A, Wallen EM, Humphreys MR, Woods ME, Castle EP. Oncologic outcomes for lymph node-positive urothelial carcinoma patients treated with robot assisted radical cystectomy: With mean follow-up of 3.5 years. Urol Oncol. 2012 Apr 23. [Epub ahead of print]
2. Nielsen ME, Smith AB, Pruthi RS, Guzzo TJ, Amiel G, Shore N, Lotan Y. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey. BJU Int. 2012 Apr 4. doi: 10.1111/j.1464-410X.2012.11060.x. [Epub ahead of print]
3. Ferguson JE 3rd, Goyal RK, Raynor MC, Nielsen ME, Pruthi RS, Brown PM, Wallen EM. Cost Analysis of Robot-Assisted Laparoscopic Versus Hand-Assisted Laparoscopic Partial Nephrectomy. J Endourol. 2012 Apr 26. [Epub ahead of print]
4. Smith AB, Raynor M, Amling CL, Busby JE, Castle E, Davis R, Nielsen M, Thomas R, Wallen EM, Woods M, Pruthi RS. Multi-institutional analysis of robotic radical cystectomy for bladder cancer: perioperative outcomes and complications in 227 patients. J Laparoendosc Adv Surg Tech A. 2012 Jan;22(1):17-21. Epub 2011 Dec 5.
5. Brannon AR, Haake SM, Hacker KE, Pruthi RS, Wallen EM, Nielsen ME, Rathmell WK. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur Urol. 2012 Feb;61(2):258-68. Epub 2011 Oct 18.
6. Manvar AM, Rathmell WK, Ferguson J, Pruthi RS, Nielsen ME, Wallen EM, Nolan N, Raynor MC. Carcinoma in a Cadaveric Transplant Kidney. Urology. 2011 Oct 18. [Epub ahead of print] No abstract available.

7. Smith AB, Raynor MC, Pruthi RS. Peri- and postoperative outcomes of robot-assisted radical cystectomy (RARC). *BJU Int*. 2011 Sep;108(6 Pt 2):969-75. doi: 10.1111/j.1464-410X.2011.10456.x. Review.
8. Raynor MC, Lavien G, Nielsen M, Wallen EM, Pruthi RS. Elimination of preoperative mechanical bowel preparation in patients undergoing cystectomy and urinary diversion. *Urol Oncol*. 2011 Jun 28. [Epub ahead of print]
9. Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS, Wallen EM, Crane JM, Moore DT, Grigson G, Morris K, Watkins CP, George DJ. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor in patients with castration-resistant prostate cancer. *Urol Oncol*, 2011 Mar 9. Epub ahead of print.
10. Coward RM, Smith A, Raynor M, Nielsen M, Wallen EM, Pruthi RS. Feasibility and outcomes of robotic-assisted laparoscopic radical cystectomy for bladder cancer in older patients. *Urology*. 2011 May;77(5):1111-4. Epub 2011 Feb 18
11. Manvar AM, Wallen EM, Pruthi RS, Nielsen ME. Prognostic value of CA 125 in transitional cell carcinoma of the bladder. *Expert Rev Anticancer Ther*, 2010; 10(12):1877-81.
12. Davis JW, Castle EP, Pruthi RS, Ornstein DK, Guru KA. Robot-assisted radical cystectomy: An expert panel review of the current status and future direction. *Urol Oncol*, 2010 Sept-Oct; 28(5):480-6. Epub 2010 Mar 5
13. Hayn MH, Hellenthal NJ, Hussain A, Andrews PE, Carpentier P, Castle E, Dasgupta P, Davis R, Thomas R, Khan S, Kibel A, Kim H, Manoharan M, Menon M, Mottrie A, Ornstein D, Peabody J, Pruthi R, Palou Redorta J, Vira M, Schanne F, Stricker H, Wiklund P, Wilding G, Guru KA. Does previous robot-assisted radical prostatectomy experience affect outcomes at robot-assisted radical cystectomy? Results from the International Robotic Cystectomy Consortium. *Urology*. 2010 Aug 13. Epub ahead of print.
14. Hayn MH, Hussain A, Mansour AM, Andrews PE, Carpentier P, Castle E, Dasgupta P, Rimmington P, Thomas R, Kahn S, Kibel A, Kim H, Manoharan M, Menon M, Mottrie A, Ornstein D, Pruthi R, Palou Redorta J, Richstone L, Schanne F, Stricker H, Wiklund P, Chandrasekhar R, Wilding GE, Guru KA. Reply from authors re: Urs E, Studer, Laurence Collette. The learning curve of robot-assisted radical cystectomy: Does it meet expectations? *Eur Urol* 2010 Aug; 58(2):204-6. Epub 2010 June 15; No abstracts available.
15. Pruthi RS, Nielsen M, Heathcote S, Wallen EM, Rathmell WK, Godley P, Whang Y, Fielding J, Schultz H, Grigson G, Smith A, Kim W. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. *BJU Int*, 2010 Aug; 106(3):349-56. Epub 2010 Jan 19.

16. Hellenthal NJ, Hussain A, Andrews PE, Carpentier P, Castle E, Dasgupta P, Kaouk J, Khan S, Kibel A, Kim H, Manoharan M, Menon M, Mottrie A, Ornstein D, Palou J, Peabody J, Pruthi R, Richstone L, Schanne F, Stricker H, Thomas R, Wiklund P, Wilding G, Guru KA. Lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. *BJU Int*, 2010 June 18. Epub ahead of print.
17. Swords K, Wallen E, Pruthi RS. The impact of race on prostate cancer detection and choice of treatment in men undergoing a contemporary extended biopsy approach. *Urol Oncol*. 2010 May-Jun; 28(3):280-4. Epub 2008 Dec 12.
18. Pruthi RS, Nix J, McRackan D, Hickerson A, Nielsen ME, Raynor M, Wallen EM. Robotic-assisted laparoscopic intracorporeal urinary diversion. *Eur Urol*, 2010 Jun; 57(6):1013-21. Epub 2010 Jan 9.
19. Hellenthal NJ, Hussain A, Andrews PE, Carpentier P, Castle E, Dasgupta P, Kaouk J, Kahn S, Kibel A, Kim H, Manoharan M, Menon M, Mottrie A, Ornstein D, Palou J, Peabody J, Pruthi R, Richstone L, Schanne F, Stricker H, Thomas R, Wiklund P, Wilding G, Guru KA. Surgical margin status after robot-assisted radical cystectomy: Results from the International Robotic Cystectomy Consortium. *J Urol*, 2010; 184(1):87-91. Epub 2010 May 15.
20. Raynor MC, Pruthi RS. Robot-assisted surgery: applications in urology. *Open Access J Urol*, 2010 May; 2010(2):85-89.
21. Hayn MH, Hussain A, Mansour AM, Andrews PE, Carpentier P, Castle E, Dasgupta P, Rimington P, Thomas R, Khan S, Kibel A, Kim H, Manoharan M, Menon M, Mottrie A, Ornstein D, Peabody J, Pruthi R, Redorta JP, Richstone L, Schanne F, Stricker H, Wiklund P, Chandrasekhar R, Wilding GE, Guru KA. The learning curve of robot-assisted radical cystectomy: Results from the International Robotic Cystectomy Consortium. *Eur Urol*, 2010; 58(2):197-202. Epub ahead of print 2010 Apr 23.
22. Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G, Watkins C, Nance KV, Crane J, Jalkut M, Moore DT, Kim WY, Godley PA, Whang YE, Fielding JR, Rathmell WK. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. *J Clin Oncol*, 2010 Mar 20; 28(9):1502-7. Epub 2010 Feb 16
23. Brannon AR, Reddy A, Seller M, Arreola A, Moore DT, Pruthi RS, Wallen EM, Nielsen ME, Liu H, Nathanson KL, Ljungberg B, Zhao H, Brooks JD, Ganesan S, Bhanot G, Rathmell WK. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. *Gene Cancer*, 2010 Feb 1; 1(2):152-163.
24. Rathmell WK, Pruthi R, Wallen E. Neoadjuvant treatment of renal cell carcinoma. *Urol Oncol*, 2010 Jan-Feb; 28(1):69-73. Review.
25. Nix J, Smith A, Kurpad R, Nielsen ME, Wallen EM, Pruthi RS. Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. *Eur Urol*, 2010 Feb; 57(2):196-201. Epub 2009 Oct 20.

26. Pruthi RS, Nielsen M, Nix J, Smith A, Schultz H, Wallen E. Robotic radical cystectomy for bladder cancer: surgical and pathological outcomes in 100 consecutive cases. *J Urol*, 2010 Feb; 183(2):510-4. Epub 2009 Dec 14.
27. Smith A, Kurpad R, Lal A, Nielsen M, Wallen E, Pruthi RS. Cost analysis of robotic versus open radical cystectomy for bladder cancer. *J Urol*, 2010 Feb; 183(2):505-9. Epub 2009 Dec 14.
28. Pruthi RS, Nielsen M, Smith A, Nix J, Kurpad R, Schultz H, Wallen E. Fast track program in patients undergoing radical cystectomy: results in 362 consecutive cases. *J of Amer College of Surgeons*, 2010 Jan; 210(1):93-99. Epub 2009 Oct 28.
29. Smith AB, Nielsen ME, Wallen EM, Pruthi RS. Current status of robot-assisted radical cystectomy. *Curr Opin Urol*, 2010 Jan; 20(1):60-4. Review.
30. Raynor M, Pruthi R. Robot-assisted surgery: applications in urology. *Open Access J of Urology*. 2010 May, vol 2;85-89.
31. Kim WY, Whang YE, Pruthi RS, Baggstrom MQ, Rathmell WK, Rosenman JG, Wallen EM, Goyal LK, Grigson G, Watkins C, Godley PA. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A phase II trial. *Urol Oncol*, 2009 Dec 21; epub ahead of print.
32. Mishel MH, Germino BB, Lin L, Pruthi RS, Wallen EM, Crandell J, Blyler D. Managing uncertainty about treatment decision making in early stage prostate cancer: a randomized clinical trial. *Patient Educ Couns*, 2009 Dec; 77(3):349-59. Epub 2009 Oct 9.
33. Kouba E, Lentz A, Wallen E, Pruthi R. Clinical use of serum CA-125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. *Urol Oncol*, 2009 Sep-Oct;27(5):486-90. Epub 2008 Jun 16.
34. Pruthi RS, Lentz AC, Sand M, Kouba E, Wallen EM. Impact of marital status in patients undergoing radical cystectomy for bladder cancer. *World J Urol*, 2009 Aug; 27(4):573-6. Epub 2009 Feb 15.
35. Pruthi RS, Belsante J, Kurpad R, Nielsen ME, Wallen EM. Robotic cystectomy and the Internet: Separating fact from fiction. *Urol Oncol*, 2009 July 2. Epub ahead of print.
36. Kurpad R, Kim W, Rathmell WK, Godley P, Whang Y, Fielding J, Smith L, Pettiford A, Schultz H, Nielsen M, Wallen E, Pruthi R. A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions? *Urol Oncol*. 2009 Jul2. Epub ahead of print.
37. Pruthi RS, Wallen EM. Current status of robotic prostatectomy: Promises fulfilled. *J Urol*, 2009 Jun; 181(6):2420-1. Epub 2009 Apr 15. No abstract available.
38. Wright TM, Brandon AR, Gordan JD, Milels AJ, Mitchell C, Chen S, Espinosa I, van de Rijn M, Pruthi R, Wallen E, Edwards L, Nusse R, Rathmell WK. Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. *Oncogene*, 2009; 28(27):2513-23. Epub 2009 May 18.

39. Satia JA, Walsh JF, Pruthi RS. Health behavior changes in white and African American prostate cancer survivors. *Cancer Nurs*, 2009 Mar - Apr; 32(2):107-17.
40. Pruthi RS, Wallen EM. Robotic-assisted laparoscopic pelvic lymphadenectomy for bladder cancer: a surgical atlas. *J Laparoendosc Adv Surg Tech A*, 2009 Feb; 19(1):71-4.
41. Pruthi RS, Stefaniak H, Hubbard JS, Wallen EM. Robotic anterior pelvic exenteration for bladder cancer in the female: outcomes and comparisons to their male counterparts. *J Laparoendosc & Adv Surg Tech A*. 2009 Feb; 19(1):23-7
42. Pruthi RS, Swords K, Schultz H, Carson CC, Wallen E. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme. *J Urol*, 2009 Feb; 181(2):574-7; discussion 578. Epub 2008 Dec 13.
43. Kimple RJ, Wallen EM, Pruthi R, Marks LB. A simple algorithm to assess patient suitability for Calypso-see implantation for four-dimensional prostate localization. *J Appl Clin Med Phys*, 2009; 11(1):3107.
44. Coward R, Simhan J, Pruthi R, Carson C. Racial differences in hypogonadal improvement and prostate-specific antigen in hypogonadal men treated with testosterone replacement therapy. *J of Mens Hlth*, 2009; 6(3):233.
45. Pruthi RS, Smith A, Wallen E. Evaluating the learning curve for robotic-assisted laparoscopic radical cystectomy. *J Endourol*, 2008 Nov; 22(11):2469-74.
46. Amin C, Wallen E, Pruthi RS, Calvo BF, Godley PA, Rathmell WK. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. *Urology*, 2008 Oct; 72(4):864-8. Epub 2008 Aug 5.
47. Pruthi RS, Stefaniak H, Hubbard JS, Wallen E. Robot-assisted laparoscopic anterior pelvic exenteration for bladder cancer in the female. *J Endourol*, 2008 Oct; 22(10):2397-402. Discussion 2402. Epub 2008 Jul 11.
48. Pruthi RS, Wallen E. Is robotic radical cystectomy an appropriate treatment for bladder cancer? Short-term oncologic and clinical follow-up in 50 consecutive patients. *Urol*, 2008 Sep; 72(3):617-20; discussion 620-2. Epub 2008 Jun 30.
49. Rathmell K, Amin C, Cowey C, Pruthi RS, Wallen E, Khandani A. Neoadjuvant therapy with sorfenib for locally advanced renal cell carcinoma (RCC). *Urol*, Epub 2008 Aug 4.
50. Kouba E, Wallen E, Pruthi RS. Management of ureteral obstruction due to advanced malignancy: optimizing therapeutic and palliative outcomes. *J Urol*, 2008 Aug; 180(2):444-50. Epub 2008 Jun 11.
51. Pruthi RS, Wallen E. Surgery in Motion: Robotic-assisted laparoscopic radical cystoprostatectomy. *Eur Urol* (paper and video). *Eur Urol*, 2008 Feb; 53(2):310-22. Epub 2007 Mar 28.

52. Hall MC, Chang SS, Dalbagni G, Pruthi R.S., Schellhammer P., Seigne J, Skinner EC, Wolf JS. Treatment principles for nonmuscle invasive bladder cancer: A review of the updated AUA guidelines. *Contemporary Urology*, 2008; 8-14.
53. Pruthi RS, Baldwin N, Bhalani V, Wallen E. Conservative management of patients with low-risk superficial bladder cancer. *J Urol*, 2008 Jan; 179(1):87-90; discussion 90. Epub 2007 Nov 12.
54. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Schellhammer P, Seigne J, Skinner EC, Wolf JS. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis). *J Urol*, 2007 Dec; 178:2314-30. Review. No abstract available.
55. Kouba E, Wallen E, Pruthi RS. Gum chewing stimulates recovery of bowel function in patients undergoing cystectomy and urinary diversion. *Urology*, 2007 Dec; 70(6):1053-6.
56. Kouba E, Sands M, Lentz A, Wallen E, Pruthi RS. Incidence and risk factors of stomal complications in patients undergoing radical cystectomy with ileal conduit urinary diversion for bladder cancer. *J Urol*, 2007 Sep; 178(3 Pt 1):950-4. Epub 2007 Jul 16.
57. Pruthi RS, Wallen E. Robotic-assisted laparoscopic radical cystoprostatectomy: operative and pathologic outcomes. *J Urol*, 2007 Sep; 178(3):814-8. Epub 2007 Jul 16.
58. Kouba E, Sands M, Lentz A, Wallen E, Pruthi RS. A comparison of the Bricker versus Wallace ureteroileal anastomosis in patients undergoing urinary diversion for bladder cancer. *J Urol*, 2007 Sep; 178(3 Pt 1):945-8; discussion 948-9. Epub 2007 Jul 16.
59. Miller J, Smith A, Kouba E, Wallen E, Pruthi RS. Prospective evaluation of short-term impact and recovery of health-related quality of life (HRQOL) in men undergoing robotic-assisted laparoscopic radical prostatectomy vs. open radical prostatectomy. *J Urol*, 2007 Sep; 178(3 Pt 1):854-8; discussion 859. Epub 2007 Jul 16.
60. Wallen E, Pruthi RS, Joyce GF, Wise M. The burden of kidney cancer in America: the urologic diseases of America project. *J Urol*, 2007 Jun; 177:2006-18; discussion 2018-9.
61. Kouba E, Smith A, Derksen JE, Gunn K, Wallen E, Pruthi RS. Efficacy and safety on en bloc ligation of the renal hilum during laparoscopic nephrectomy. *Urology*, 2007 Feb; 69(2):226-9. Epub 2007 Jan 31.
62. Kouba E, Smith A, McRackan D, Wallen E, Pruthi RS. Watchful waiting for solid renal masses: insight into the natural history and the results of delayed intervention. *J Urol*, 2007 Feb; 177(2):466-70; discussion 470.
63. McLaughlin S, Shephard J, Wallen E, Maygarden S, Carson CC, Pruthi RS. Comparison of the clinical and pathologic staging in patients undergoing radical cystectomy for bladder cancer. *Int Braz J Urol*, 2007 Jan-Feb; 33(1):25-31; discussion 31-2.
64. Kouba E, Evans A, Gaston KE, Lavelle JP, Pruthi RS. From simple urinary tract infection to transitional cell carcinoma of the bladder: evaluation of patients with irritative voiding symptoms. *Issues in Urology*, 2007; pp. 43-48.

65. Kouba E, Hubbard JS, Wallen E, Pruthi RS. Incisional hernia in a 12 mm non-bladed trocar site following laparoscopic nephrectomy. *Urol Int*, 2007; 79 (3):276-9.
66. Pruthi RS, Hubbard JS, Kouba E, Wallen EM. Androgen-independent prostate cancer treated with resection of the solitary metastatic site. *Urol Int*, 2007; 79(4):371-3.
67. Kouba E, Wallen E, Pruthi RS. Uroscopy by Hippocrates and Theophilus: prognosis versus diagnosis. *J Urol*, 2007 Jan; 177(1):50-2.
68. Kouba E, Hubbard JS, Moore D, Wallen E, Pruthi RS. Prospective evaluation of short-term impact and recovery of health-related quality of life in men undergoing radical prostatectomy. *BJU Int*, 2007 Jan; 99(1):72-6.
69. Tornehl C, Derksen JE, Maygarden S, Connolly AM, Pruthi RS. Bladder leiomyoma resection facilitated by abdominal development of the paravaginal space. *Issues in Urology*, 2007; p. 14-17.
70. Pruthi RS, Kouba E, Carson CC, Wallen E. Cyclooxygenase-2 inhibitors and other NSAIDs in urology: current peril or future promise. *Urology*, 2006 Nov; 68(5):917-23. Review. No abstract available.
71. Pruthi RS, Tornehl C, Gaston K, Lee K, Moore D, Carson C, Wallen E. Impact of race, age, income and residence on prostate cancer knowledge, screening behavior and health maintenance in siblings of patients with prostate cancer. *Eur Urol*, 2006 Jul; 50(1):64-9. Epub 2005 Dec 12.
72. Pruthi RS, Kouba E, Hubbard JS, Funkhouser W, Wallen E. Large presacral schwannoma after radical prostatectomy: Part 2. *Eur Urol*, June 2006; pp 968-971.
73. Pruthi RS, Hubbard JS, Kouba E, Funkhouser W, Wallen E. Short Survey: Large presacral schwannoma after radical prostatectomy. *Eur Urol*, 2006 May;49(5): 914-7. Epub 2006 Feb 24.
74. Gaston KE, Pruthi RS. Racial differences in prostate cancer. *NC Med J*, 2006 Mar-Apr; 67(2):130-5.
75. Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C, Wallen E. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. *Clin Cancer Res*, 2006 Apr 1; 12(7 Pt 1):2172-7.
76. Kouba E, Hubbard JS, Wallen E, Pruthi RS. Incisional hernia in a 12 mm non-bladed trocar site following laparoscopic nephrectomy. *TSW Urol*, 2006 Mar 26; 6:2399-402 .
77. Thomas R, Albala DM, Castle EP, Pruthi RS. Symposium: Robotic surgery in urology: Hype, hope, and reality. *Contemporary Urology*, 2006; p. 26-32.
78. Fielding JR, Borland D, Lee KH, Clarke JP, Wallen E, Pruthi R, Taylor RM. Virtual pyeloscopy using volumetric depth peeling. *Acad Radiol*, 2006; 13(6):759-63.

79. Gaston KE, Kouba E, More DT, Pruthi RS. The use of erythropoietin in patients undergoing radical prostatectomy: effects on hemtocrit, transfusion rates, and quality of life. *Urol Int*, 2006; 77(3):211-5.
80. Moliterno J, Evans A, Mohler JL, Moore D, Pruthi RS. Characterization of biochemical recurrence after radical prostatectomy. *Urol Int*, 2006; 77(2):130-4.
81. Derksen JE, Pruthi RS. A case of urachal adenocarcinoma in a young female treated with partial cystectomy. *Issues in Urology*, 2006; pp.14-17.
82. Smith JA, Cookson M, Hall MC, Keane TE, Pruthi RS. Confronting a rising PSA after prostatectomy. *Patient Care*, 2005; pp 16-22.
83. Pruthi RS, Wallen E. Cyclooxygenase-2: a therapeutic target for prostate cancer. *Clin Genitourin Cancer*, 2005; 4(3):203-11.
84. Hubbard JS, Pruthi RS, Wallen EM. A guide to understanding and minimizing the complications of laparoscopic urologic surgery. *Contemporary Urology*, 2005; p 46-51.
85. Maygarden SJ, Pruthi RS. Gleason grading and volume estimation in prostate needle biopsies: evolving issues. *Am J Clin Pathol*, 2005; 123 Suppl:S58-66.
86. Kouba E, Evans AJ, Gaston K, Wallen EW, Pruthi RS. Cystitis, carcinoma, and the use of urinary cytology. *Issues in Urology*, 2005; pp.1-7.
87. Richman M, Pruthi RS. Laparoscopic excision of parapelvic renal cyst causing obstructive uropathy. *Issues in Urology*, 2005; pp 1-4.
88. Stefaniak HM, Wallen E, Pruthi RS. The contribution of race to prostate cancer outcome – tumor biology versus socioeconomic and behavioral factors. *Contemporary Urology*, 2005; 66-70.
89. Richman M, McLaughlin S, Maygarden S, Pruthi RS. Initial incision of the lateral pelvic fascia and early ligation of the vascular pedicles during radical prostatectomy: potential to reduce positive margin rates. *BJU Int*, 2005 Jan; 95(1):40-5.
90. Pruthi RS, Derksen JE, Gaston K, Wallen EW. Rationale for the use of COX-2 inhibitors in prevention and treatment of bladder cancer. *Urology*, 2004 Oct; 64(4):637-42.
91. Kouba E, Tornehl C, Lavelle J, Wallen E, Pruthi RS. Partial nephrectomy with fibrin glue repair: measurement of vascular and pelvicaliceal bond integrity in a live porcine and isolated abattoir animal model. *J Urol*, 2004 Jul; 172: 326-30.
92. Gaston K, Pruthi RS. Value of urinary cytology in the diagnosis and management of urinary tract malignancies. *Urology*, 2004 Jun; 63(6):1009-16
93. Pruthi RS, Chun J, Richman M. The use of a fibrin tissue sealant during laparoscopic partial nephrectomy. *BJU Int*, 2004 Apr; 93:813-7.
94. Richman M, Moliterno J, Pruthi RS. Retroperitoneal cyst of the lienorenal ligament. *Urology*, 2004 Feb; 63(2): 379.

95. Pruthi RS, Derksen JE, Moore D. A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. *BJU Int*, 2004 Feb; 93(3):275-8.
96. Chun J, Pruthi RS. Is neoadjuvant hormonal therapy before radical prostatectomy indicated? *Urol Int*, 2004; 72(4):275-80.
97. Smith JA, Cookson M, Hall MC, Keane TE, Pruthi RS. Confronting a rising PSA after prostatectomy. *Contemporary Urology*, 2004; 16: 34-46.
98. Kang J, Mohler JL, Pruthi RS. Comparison of clinical and pathological features in African American and Caucasian patients with localized prostate cancer. *BJU Int*, 2004; 93 :1207-10.
99. Derksen E, Pruthi RS. COX-2 inhibitors in PSA-recurrent prostate cancer: a pilot study. *BJU Int*, 2004; 93: 275-8.
100. Gaston K, Moore DT, Pruthi RS. Hand-assisted laparoscopic nephrectomy: prospective evaluation of the learning curve. *J Urol*, 2004 Jan; 171(1); 63-7.
101. Pruthi RS, Richman M, Derksen JE, Maygarden S. Stage T1 renal cell carcinoma relapsing in the vagina 10 years after initial diagnosis. *J Urol*, 2003 Dec; 170(6 Pt 1): 2379-80.
102. Pruthi RS, Chun J, Richman M. Reducing time to oral diet and hospital discharge in patients undergoing radical cystectomy using a perioperative care plan. *Urology*, 2003 Oct; 62(4): 661-5; discussion 665-6.
103. Pruthi RS, Derksen JE, Gaston K. Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. *J Urol*, 2003 June; 169(6): 2352-9.
104. Pruthi RS, Gaston K, Derksen JE. Regarding effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. *J Urol*, 2003 Jun; 169(6):2304; author reply 2304-5.
105. Pruthi RS, Chun J, Richman M. Hand-assisted laparoscopic nephrectomy: complications related to the handport site. *BJU Int*, 2003 Apr; 91(6):584-5.
106. Pruthi RS, Issa MM, Fielding J. Evaluation and treatment of the incidental adrenal mass. *Contemporary Urology*, 2003 Apr; 43-55.
107. Pruthi RS, Derksen JE. Use of the COX-2 inhibitor celecoxib in PSA-recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. *Prostate Cancer and Prostatic Diseases*, 2003; 6 (Suppl 1): S30.

108. Gaston K, Lee K, Pruthi RS. Impact of race, income, and residence on prostate cancer knowledge, screening behavior, and health maintenance in sibling of patients with prostate cancer. *J American College of Surgeons*, 2003; 197 (3 Suppl): S92.
109. Pruthi RS. PSA doubling time may point to cancer aggressiveness. *Urology Times*, 2003; 31(3), 32.
110. Derksen JE, Fitzsimmons N, Ornstein D, Pruthi RS. Early urethral catheter removal after radical retropubic prostatectomy. *J American College of Surgeons*, 2003; 197 (3 Suppl): S92.
111. Small E, Halabi S, Dalgagni G, Pruthi R, Phillips G, Edelman M, Bajorin D. Overview of bladder cancer trials in the cancer and leukemia group B. *Cancer*, 2003; 97(8 Suppl): 2090-8.
112. Pruthi RS, Kang J, Vick R. Desmopressin-induced hyponatremia and seizures after laparoscopic radical nephrectomy. *J Urol*, 2002 Jul; 168(1):187.
113. Chun J, Pruthi RS. The role of neoadjuvant hormonal therapy before radical prostatectomy. *The Prostate Journal*, 2002; 4(4):86-90.
114. Pruthi RS, Richman M, Ornstein DK. A case of T1c, N3, M1 prostate cancer. *Urol Int*, 2002; 69(1):82-4.
115. Ornstein DK, Pruthi RS. Prostate-specific antigen. *Expert Opin Pharmacother*, 2000 Dec; 1(7):1399-1411.
116. Pruthi RS. Regarding prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. *J Urol*, 2000 Dec; 164(6):2031.
117. Pruthi RS, Petrus CD, Bundrick WS Jr. New onset vesicovaginal fistula after transurethral collagen injection in women who have undergone cystectomy and orthotopic neobladder creation: presentation and definitive treatment. *J Urol*, 2000 Nov; 164(5):1638-9.
118. Pruthi RS. The dynamics of PSA in benign and malignant diseases of the prostate. *BJU Int*, 2000 Oct; 86(6):652-8.
119. Pruthi RS, Petrus CD, Nidess R, Venable DD. Penile fracture of the proximal corporal body. *J Urol*, 2000 Aug; 164(2):447-8.
120. Petrus CD, Pruthi RS. Crossed renal ectopia with an associated ureteral stone: sonographic, CT, and pyelographic findings. *Infections in Urology*, 2000; 13(6):159-62.
121. Pruthi RS. PSA Kinetics: A review of PSA doubling times and half-lives in patients with treated and untreated prostate cancer. *The Prostate Journal*, 2000; 2(4).
122. Pruthi RS. The value of urine cytology in the diagnosis and management of urinary tract malignancies. *Pathology Case Reviews*, 2000; 5(2):102-5.

123. Pruthi RS, Angell SA, Brooks JD, Gill HG. Partial nephrectomy and caval thrombectomy for renal cell carcinoma in a solitary kidney with an accessory renal vein. *BJU Int*, 1999 Jan; 83(1):142-3.
124. Angell SA, Pruthi RS, Shortliffe LD. The urodynamic relationship of renal pelvic and bladder pressures, and urinary flow rate in rats with congenital vesicoureteral reflux. *JUrol*, 1998 Jul; 160(1):150-6.
125. Pruthi RS. Regarding recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. *J Urol*, 1998 May; 159(5):1650.
126. Angell SA, Pruthi RS, Gill H. A testicular teratoma with a unique mode of spread. *Urol Int*, 1998; 61(2):119-20.
127. Pruthi RS, Terris MK, Issa MI, Kabalin J.K. Renal masses presenting 25 and 50 years following blunt renal trauma. *Urol Int*, 1998; 61(1):43-6.
128. Pruthi RS, Angell SA, Dubocq F, Merguerian PA, Shortliffe LD. The use of renal parenchymal area in children with high grade vesicoureteral reflux. *J Urol*, 1997 Sep; 158(3 Pt 2):1232-5.
129. Pruthi RS, Johnstone I, Tu IP, Stamey TA. PSA doubling times in patients who fail radical prostatectomy: correlation with histologic characteristics of the primary cancer. *Urology*, 1997 May; 49(5):737-42.
130. Pruthi RS, Haese A, Huland E, Stamey TA. The use of serum concentration techniques to enhance early detection of recurrent prostate cancer after radical prostatectomy. *Urology*, 1997 Mar; 49 (3):404-10.
131. Issa MM, Mc, Pruthi RS, Namara D. New technique of ureteral stent placement impacted ureteral calculus: the guidewire loop technique. *Urology*, 1997 Apr; 49 (4):614-7.
132. Issa MM, Pruthi RS, Vial C, McNamara DE, Terris MK. An unusual complication following uroflowmetry: hyponatremia and seizure. *Urologia Internationalis*, 1997; 59(2):129-30.
133. Pruthi RS, Angell SK, Gill H. Furuncular myiasis of the scrotum. *Infections in Urology*, 1997; 10 (4):102-4.
134. Angell SA, Pruthi RS, Merguerian PA. Pediatric genitourinary tumors. *Curr Opin Oncol*, 1996 May; 8(3):240-6.
135. Angell SA, Pruthi RS, Freiha FS. A primary thyroid-like carcinoma of the kidney. *Urology*, 1996; 48 (4): 632-5.

136. Pruthi RS, Angell SA, Dubocq F, Merguerian PA, Shortliffe LD. Use of longitudinal renal parenchymal area in children with high grade vesicoureteral reflux. *Pediatrics*, 1996; 98 (3):619.
137. Farouk M, Vigna SV, Haebig JA, Gettys TW, McVeyDC, Chari R, Pruthi RS, Meyers WC. Secretin receptors in a new preparation of plasma membranes from intrahepatic biliary epithelium. *Journal of Surgical Research*, 1993 Jan; 54:1-6.
138. Pruthi RS, Farouk M, Tsai WS, Michalopoulos G, Meyers WC. The effect of octreotide on hepatic regeneration in rats. *Surgery*, 1993 Jan; 113(1):84-9.
139. Farouk M, Geoghegan JG, Pruthi RS, Pappas TN, Meyers WC. ICV neuropeptide Y stimulates bile duct secretion via a vagal mechanism. *Gut*, 1992 Nov; 33(11):1562-5.
140. Pruthi RS, Farouk M, Meyers WC. Somatostatin analogue inhibits hepatic regeneration. *Surgical Forum*, 1991; 42:144-7.
141. Farouk M, Pruthi RS, Meyers WC. The appearance and characterization of intrahepatic secretin receptors following common bile duct ligation. *Surgical Forum*, 1991; 42:156-9.
142. Meyers WC, Farouk M, Pruthi RS, et al.(Southern Surgeon's Club). A prospective analysis of 1518 laparoscopic cholecystectomies. *New England J Med*, 1991; 324:1073-8.
143. Prosser ES, Pruthi RS, Csernansky JG. Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride. *Psychopharmacology*, 1989; 99:109-16.
144. Csernansky JG, Kerr S, Pruthi RS, Prosser ES. Mesolimbic dopamine receptor increases two weeks after hippocampal kindling. *Brain Research*, 1988; 449:357-60.

Editorials

1. Smith A, Pruthi RS. The impact of comorbidity on survival of invasive bladder cancer patients, 1996-2007: a Danish population-based cohort study. Editorial Comment on Article (Invited), *Urology*, 2010 Feb; 75(2):398.
2. Nix J, Pruthi RS. Significance of distal ureteral margin at radical cystectomy for urothelial carcinoma. Invited Editorial Comment. *J Urol*, 2010 Jan; 183(1):86; discussion 86. Epub. No abstract available.
3. Nix J, Pruthi RS. Reply from Authors re: Oliver W. Hakenberg. Moving towards evidence-based surgery. *Eur Urol*. In press. Doi:10.1016/j.eurouro.2009.11.003, *Eur Urol*, 2009 November 25. Epub ahead of print. No abstract available.
4. Pruthi RS. Editorial Comment in re: Lowrance WT, Rumohr JA, Chang SS, Clark PE, Smith JA Jr, Cookson MS. Contemporary open radical cystectomy: analysis of perioperative outcomes. *J Urol*, 2008; 179(4):1313-8.

5. Pruthi RS. Editorial Comment in re: Tokgoz H, Turkolmez K, Resorlu B, Kose K, Tulunay O, Beduk Y. Pathological staging of muscle invasive bladder cancer. Is substaging of pT2 tumors really necessary? *Int Braz J Urol*, 2007; 33(6):777-84.
6. Pruthi RS. Editorial Comment in re: Stopping smoking might reduce tumor recurrence in nonmuscle-invasive bladder cancer. *BJU Int*. 2007 April 5 (epub ahead of print).
7. Pruthi RS. Editorial Comment in re: Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. *J Urol*, 2006; 176(3):979-84; discussion 984.
8. Pruthi RS. Editorial Comment in re: Expression of COX-2 in normal and pyelonephritic kidney, renal intraepithelial neoplasia and renal cell carcinoma. *Eur Urol*, 2006; 50(1):92-7.
9. Pruthi RS. Editorial Comment in re: Long-term benefit of 5-Aminolevulinic acid-fluorescence-assisted transurethral resection of superficial bladder cancer: five-year results of a prospective randomized study. *J Urol*, 2005; 175: 2291-91.

Abstracts and Scientific Presentations (refereed)

1. Ian Udell, Raj Kurpad, Angela Smith, Michael Woods, Eric Wallen, Raj Pruthi, Matthew Nielsen. Surveillance Guidelines for Low Grade Non-Invasive Bladder Cancer: A Cost Comparison. American Urological Association, May 22, 2012. Atlanta, GA.
2. Ian Udell, Raj Kurpad, Angela Smith, Jeff Nix, Matthew Nielsen, Eric Wallen, Michael Woods, Raj Pruthi. Prospective Randomized Controlled Trial of Robotic Versus Open Radical Cystectomy for Bladder Cancer: Median 3-Year Follow-Up Results. American Urological Association, May 22, 2012. Atlanta, GA.
3. Ian Udell, Raj Kurpad, Jed Ferguson, Angela Smith, Matthew Nielsen, Eric Wallen, Michael Woods, Raj Pruthi. An evaluation of Neoadjuvant chemotherapy eligibility rates among patients undergoing radical Cystectomy for bladder cancer. American Urological Association, May 22, 2012. Atlanta, GA.
4. Ian Udell, Raj Kurpad, Angela Smith, Matthew Nielsen, Eric Wallen, Michael Woods, Raj Pruthi. Long-Term Follow-Up of Patients Initially Managed with Active Surveillance for Solid Renal Masses. American Urological Association, May 22, 2012. Atlanta, GA.
5. Matthew H Hayn, Ahmed El-Nahas, Andrew P Stegemann, Piyush K Agarwal, Ketan K Badani, M Derya Balbay, Erik P Castle, Prokar Dasgupta, Reza Ghavamian, Ashok K Hemal, Brent K Hollenbeck, David Josephson, A Karim Kader, Shamim Kahn, Adam S Kibel, Mani Menon, Alex Mottrie, Kenneth Nepple, John G Pattaras, James O Peabody, Vassilis Poulakis, Raj S Pruthi, et.al. Is Robot-Assisted Cystectomy Effective for T3 Bladder Cancer? Results from the International Robotic Cystectomy Consortium. American Urological Association, May 22, 2012. Atlanta, GA.

6. Ian Udell, Raj Kurpad, Jed Ferguson, Angela Smith, Matthew Nielsen, Eric Wallen, Michael Woods, Raj Pruthi. "Cost Analysis of Robotic-Assisted Radical Cystectomy versus open Radical Cystectomy Utilizing a Prospective, Randomized cohort. American Urological Association, May 21, 2012. Atlanta, GA.
7. Kamran Ahmed, Matthew H Hayn, Andrew P Stegemann, Piyush K Agarwal, Ketan K Badani, M Derya Balbay, Erik P Castle, Prokar Dasgupta, Reza Ghavamian, Khurshid A Guru, Ashok K Hemal, Brent K Hollenbeck, David Josephson, A Karim Kadar, Adam S Kibel, Mani Menon, Alex Mottrie, Kenneth Nepple, John G Pattaras, James O Peabody, Vassilis Poulkis, Raj S Pruthi, et.al. Comparison of Outcomes Between Intra-Corporeal and Extra-Corporeal Urinary Diversion After Robot-Assisted Radical Cystectomy-The IRCC Results. American Urological Association, May 21, 2012. Atlanta, GA.
8. Ian Udell, Raj Kurpad, Angela Smith, Matthew Nielsen, Raj Pruthi, Eric Wallen, Michael Woods, William Kim. Defining the Molecular Determinants of Sensitivity to EGFR Inhibition in Urothelial Carcinoma. American Urological Association, May 21, 2012. Atlanta, GA.
9. Simon Neuwahl, Raj Kurpad, Erin Fraher, Thomas Ricketts, George Sheldon, Howard Snyder, Matthew Nielsen, Raj Pruthi. An Analysis of the Supply of Urologic Surgeons in the United States. American Urological Association, May 20, 2012. Atlanta, GA.
10. Lixin Song, Raj Kurpad, Ian Udell, Jeanette Bensen, Angela Smith, Matthew Nielsen, Eric Wallen, Michael Woods, Raj Pruthi, James Mohler. "Who Makes The Decision Regarding Treatment for Localized Prostate Cancer, Patient or Physician? Results from A Population-Based Study". American Urological Association, May 20, 2012. Atlanta, GA.
11. Scott Haake, A. Rose Brannon, Raj Kurpad, Ian Udell, Angela Smith, Matthew Nielsen, Raj Pruthi, Eric Wallen, Michael Woods, W. Kim Rathmell. Clear cell renal cell carcinoma displays differential gene expression based on gender. American Urological Association, May 20, 2012. Atlanta, GA.
12. A. Rose Brennan, Scott Haake, Raj Kurpad, Ian Udell, Angela Smith, Matthew Nielsen, Raj Pruthi, Eric Wallen, Michael Woods, W. Kim Rathmell. Meta-Analysis of Clear Cell Renal Cell Carcinoma Gene Expression Delineates Subgroups. American Urological Association, May 20, 2012. Atlanta, GA.
13. Simon Neuwahl, Ian Udell, Erin Fraher, Thomas Ricketts, George Sheldon, Howard Snyder, Matthew Nielsen, Raj Pruthi. Practice Type and Employment of Urologists in the United States: An Analysis of Changes Over the Decade. American Urological Association, May 19, 2012. Atlanta, GA.
14. Ian Udell, Raj Kurpad, Ankur Manvar, Matthew Nielsen, Mathew Raynor, Angela Smith, Eric Wallen, Michael Woods and Raj Pruthi. The Affect on the Long-Term Emotional and Physical Well-being of Patients Undergoing Radical Cystectomy. Southeastern Section of the American Urological Association, March 25, 2012. Amelia Island, Florida.
15. Raj Kurpad, Ian Udell, Matthew Nielsen, Michael Woods, Raj Pruthi, Eric Wallen and Mathew Raynor. Robot-Assisted Retroperitoneal Partial Nephrectomy: Initial Clinical Experience and Outcomes. Southeastern Section of the American Urological Association, March 25, 2012. Amelia Island, Florida.

16. Ian Udell, Raj Kurpad, Ankur Manvar, Matthew Nielsen, Angela Smith, Eric Wallen, Michael Woods and Raj Pruthi. The Quality of Prostate Cryotherapy Information on the Internet. Southeastern Section of the American Urological Association, March 25, 2012. Amelia Island, Florida.
17. Raj Pruthi, Learning Curve and Cost. UC San Diego Urology Postgraduate Course Masters Robotics for Urologic Oncology and Pelvic Reconstruction, March 24, 2012.
18. Raj Pruthi, Urinary Diversion during Robotic Cystectomy. UC San Diego Urology Postgraduate Course Masters Robotics for Urologic Oncology and Pelvic Reconstruction, March 24, 2012.
19. Raj Pruthi, Optimizing Outcomes with a Clinical Care Pathway, UC San Diego Urology Postgraduate Course Masters Robotics for Urologic Oncology and Pelvic Reconstruction, March 24, 2012.
20. Raj Pruthi, Special Cases-Prostate Sparing/Female, UC San Diego Urology Postgraduate Course Masters Robotics for Urologic Oncology and Pelvic Reconstruction, March 24, 2012.
21. Raj Kurpad, Ian Udell, Matthew Nielsen, Mathew Raynor, Angela Smith, Eric Wallen, Michael Woods, Raj Pruthi and Kim Rathmell. Recurrence and Survival Following Preoperative Sorafenib for Advanced Renal Cell Carcinoma. Southeastern Section of the American Urological Association, March 23, 2012. Amelia Island, Florida.
22. Raj Kurpad, Ian Udell, Sophia Delphe, Matthew Nielsen, Mathew Raynor, Eric Wallen, Michael Woods, Raj Pruthi and Angela Smith. Single Institution Evaluation of Patterns of Care for Renal Cell Carcinoma: A 5-Year Analysis. Southeastern Section of the American Urological Association, March 23, 2012. Amelia Island, Florida.
23. Raj Kurpad, Ian Udell, Rose Brannon, Scott Haake, Matthew Nielsen, Mathew Raynor, Eric Wallen, Michael Woods, Raj Pruthi and Kim Rathmell. Meta-Analysis of Clear Cell Renal Cell Carcinoma Gene Expression Delineates Subgroups. Southeastern Section of the American Urological Association, March 23, 2012. Amelia Island, Florida.
24. Ian Udell, Raj Kurpad, Raj Pruthi, Mathew Raynor, Angela Smith, Eric Wallen, Michael Woods and Matthew Nielsen. Surveillance Protocols for Localized Kidney Cancer: A Cost Comparison. Southeastern Section of the American Urological Association, March 23, 2012. Amelia Island, Florida.
25. Ian Udell, Raj Kurpad, Matthew Nielsen, Mathew Raynor, Angela Smith, Eric Wallen, Michael Woods and Raj Pruthi. Robotic-Assisted Laparoscopic Intracorporeal Urinary Diversion: Combined Initial Experience. Southeastern Section of the American Urological Association, March 23, 2012. Amelia Island, Florida.
26. Ian Udell, Raj Kurpad, Matthew Nielsen, Michael Woods, Raj Pruthi, Eric Wallen and Mathew Raynor. Robot-Assisted Ureteral Reconstruction: Initial Clinical Experience and Outcomes. Southeastern Section of the American Urological Association, March 23, 2012. Amelia Island, Florida.

27. Ian Udell, Raj Kurpad, Andrew Blackburne, Matthew Nielsen, Mathew Raynor, Angela Smith, Eric Wallen, Michael Woods and Raj Pruthi. Robotic Partial Nephrectomy and the Internet: Is the Information Evidenced –Based? Southeastern Section of the American Urological Association, March 23, 2012. Amelia Island, Florida.
28. Ian Udell, Raj Kurpad, Raj Pruthi, Mathew Raynor, Angela Smith, Eric Wallen, Michael Woods and Matthew Nielsen. Surveillance Guidelines for Low Grade Non-Invasive Bladder Cancer: A Cost Comparison. Southeastern Section of the American Urological Association, March 22, 2012. Amelia Island, Florida.
29. Raj Kurpad, Ian Udell, Matthew Nielsen, Mathew Raynor, Angela Smith, Eric Wallen, Michael Woods and Raj Pruthi. The Impact of Radical Cystectomy on Renal Function: An Analysis of Variance Based on Age, Gender, Race and Diversion Technique. Southeastern Section of the American Urological Association, March 22, 2012. Amelia Island, Florida.
30. Ian Udell, Raj Kurpad, Mathew Raynor, Angela Smith, Eric Wallen, Michael Woods, Raj Pruthi and Matthew Nielsen. Reported Patterns of Utilization of Intravesical Therapy in Non-Muscle –Invasive Bladder Cancer: Results From the BCAN/SUO/AUA/LUGPA Electronic Survey. Southeastern Section of the American Urological Association, March 22, 2012. Amelia Island, Florida.
31. Raj Kurpad, Ian Udell, Jeff Nix, Matthew Nielsen, Eric Wallen, Michael Woods, Raj Pruthi and Angela Smith. Prospective Randomized Controlled Trial of Robotic Versus Open Radical Cystectomy for Bladder Cancer: Median 3-Year Follow-Up Results. Southeastern Section of the American Urological Association, March 22, 2012. Amelia Island, Florida.
32. Raj Kurpad, Ian Udell, Jed Ferguson, Angela Smith, Matthew Nielsen, Eric Wallen, Michael Woods and Raj Pruthi. An Evaluation of Neoadjuvant Chemotherapy Eligibility Rates among Patients Undergoing Radical Cystectomy for Bladder Cancer. Southeastern Section of the American Urological Association, March 22, 2012. Amelia Island, Florida.
33. Raj Kurpad, Ian Udell, Matthew Nielsen, Mathew Raynor, Angela Smith, Eric Walln, Michael Woods and Raj Pruthi. Use and Outcomes of Adjuvant Chemotherapy in PT3-4 Or Node Positive Bladder Cancer: Analysis of Modern Surgical Cohort. Southeastern Section of the American Urological Association, March 22, 2012. Amelia Island, Florida.
34. Raj Kurpad, Ian Udell, Ankur Manvar, Matthew Nielsen, Mathew Raynor, Angela Smith, Eric Wallen, Michael Woods and Raj Pruthi. Outcomes with Intravesical Therapy in Patients with Initial T1 Bladder Cancer. Southeastern Section of the American Urological Association, March 22, 2012. Amelia Island, Florida.
35. Raj Kurpad, Ian Udell, Jed Ferguson, Matthew Nielsen, Mathew Raynor, Angela Smith, Eric Wallen, Michael Woods and Raj Pruthi. An Evaluation of Adjuvant Chemotherapy Eligibility Rates among Patients Undergoing Radical Cystectomy. Southeastern Section of the American Urological Association, March 22, 2012. Amelia Island, Florida.

36. Ian Udell, Raj Kurpad, Raj Pruthi, Mathew Raynor, Angela Smith, Eric Wallen, Michael Woods, and Matthew Nielsen. The Cost Impact of Addition of NMP22 Bladderchek to Non-Invasive Bladder Cancer Surveillance. Southeastern Section of the American Urological Association, March 22, 2012. Amelia Island, Florida.
37. Raj Kurpad, Ian Udell, William Kim, Matthew Nielsen, Mathew Raynor, Angela Smith, Eric Wallen, Michael Woods and Raj Pruthi. Defining the Molecular Determinants of Sensitivity to EGFR Inhibition in Urothelial Carcinoma. Southeastern Section of the American Urological Association, March 22, 2012. Amelia Island, Florida.
38. Ian Udell, Raj Kurpad, Jed Ferguson, Matthew Nielsen, Mathew Raynor, Angela Smith, Eric Wallen, Michael Woods and Raj Pruthi. Cost Analysis of Robotic-Assisted Radical Cystectomy versus Open Radical Cystectomy Utilizing a Prospective, Randomized Cohort. Southeastern Section of the American Urological Association, March 22, 2012. Amelia Island, Florida.
39. Ian Udell, Raj Kurpad, Raj Pruthi, Mathew Raynor, Angela Smith, Eric Wallen, Michael Woods and Matthew Nielsen. The Cost Impact of Addition of Urovysion Fish to Non-Muscle-Invasive Bladder Cancer Surveillance. Southeastern Section of the American Urological Association, March 22, 2012. Amelia Island, Florida.
40. Busby, JE, Pruthi, RS. Moderator Session 10: Bladder & Prostate Cancer Poster Session. Southeastern Section of the American Urological Association, March 22, 2012. Amelia Island, FL.
41. Raj S. Pruthi. Robotic Neobladder: Video. Miami Robotics Symposium, February 17, 2012. Miami, FL.
42. Raj S. Pruthi. State-Of-the Art Lecture: Robotic Cystectomy. Robotics Symposium, February 17, 2012. Miami, FL.
43. Raj S. Pruthi. Introduction: Why Bladder Cancer? American College of Surgeons Clinical Congress, October 26, 2011, San Francisco, CA.
44. Raj S. Pruthi. Future Directions: Where do we go from here? American College of Surgeons Clinical Congress, October 26, 2011, San Francisco, CA.
45. Raj S. Pruthi. Trends in Regionalization of Adrenalectomy to Higher Volume Surgical Centers. Discussant, Surgical Forum Session. American College of Surgeons Clinical Congress, October 24, 2011, San Francisco, CA.
46. John P. Selph, Joshua Langston, Gilad Amiel, Tom Guzzo, Yair Lotan, Neal Shore, Angela Smith, Eric Wallen, Raj Pruthi, Matthew Nielsen. Patterns of Utilization of Urine-Based Markers in Non-Muscle-Invasive Bladder Cancer: Results from the BCAN / SUO / AUA / LUGPA Electronic Survey. Surgical Forum Session American College of Surgeons Clinical Congress, October 24, 2011, San Francisco, CA.

47. Shayn M, Stegeman A, Agarwal P, Badani K, Balbay M, Castle E, Dasgupta P, Hellenthal N, Hemal A, Josephson D, Kader A, Kibel A, Mottrie A, Nepple K, Pattaras J, Peabody J, Poulakis V, Pruthi R, Redorta J, Rha K, Richstone L, Saar M, Scherr D, Siemer S, Stoeckle M, Wallen E, Wiklund P, Wilson T, Woods M, Uyh B, Guru K. Pathologic and early oncologic outcomes after robotic-assisted radical cystectomy: Results from the International Robotic-Cystectomy Consortium. American Urological Association, May 17, 2011. Washington, DC.
48. Marshall S, Hayn M, Stegemann A, Agarwal P, Badani K, Balbay M, Castle E, Dasgupta P, Hemal A, Josephson D, Kader A, Kibel A, Mottrie A, Nepple K, Pattara J, Peabody J, Poulakis V, Pruthi R, Redorta J, Rha K, Richstone L, Saar M, Scherr D, Siemer S, Stoeckle M, Wallen E, Wiklund P, Wilson T, Woods M, Yuh B, Guru K. Lymph node yield and predictors of extended lymphadenectomy at the time of robot-assisted radical cystectomy: Results from the International Robotic Cystectomy Consortium. American Urological Association, May 17, 2011. Washington, DC.
49. Selph JP, Raynor M, Langston J, Smith A, Nielsen M, Wallen E, Pruthi R. The stepwise approach to robotic-assisted laparoscopic intracorporeal urinary diversion. American Urological Association, May 17, 2011. Washington, DC.
50. Selph JP, Raynor M, Langston J, Smith A, Nielsen M, Wallen E, Pruthi R. Initial experience with robotic-assisted approaches to partial cystectomy. American Urological Association, May 17, 2011. Washington, DC.
51. Chinedu M, Nunez R, Pruthi R, Nielsen M, Wallen E, Smith A, Hunphreys M, Castle E. Robotic Radical Cystectomy: Medium-Term Oncologic Follow-Up. American Urological Association, May 17, 2011. Washington, DC.
52. Langston J, Selph JP, Manvar A, Ferguson J, Smith A, Raynor M, Nielsen M, Wallen E, Pruthi R. The evaluation of the learning curve associated with robotic radical cystectomy: Initial 100 cases. American Urological Association, May 16, 2011. Washington, DC.
53. Langston J, Raynor M, Selph P, Mmeji C, Nielsen M, Wallen E, Castle E, Pruthi R. Robotic-assisted laparoscopic intracorporeal urinary diversion: Combined initial experience. American Urological Association, May 16, 2011. Washington, DC.
54. Langston J, Ferguson, Selph JP, Smith A, Raynor M, Nielsen M, Wallen E, Pruthi R. Cost analysis of robotic-assisted radical cystectomy versus open radical cystectomy utilizing a prospective, randomized cohort. American Urological Association, May 14, 2011. Washington, DC.
55. Pruthi RS, Castle E, Davis JW. Robot assisted radical cystectomy and extended lymphadenectomy. American Urological Association, May 14, 2011. Washington, DC.
56. Pruthi RS. Radical cystectomy and urinary diversion in bladder cancer. Urology Nursing Society "Urology Nursing 2011", March 24, 2011. Chapel Hill, North Carolina.

57. Langston J, Selph JP, Ferguson J, Manvar A, Sawh S, Raynor M, Nielsen M, Wallen E, Pruthi R. Cost analysis of robotic-assisted versus laparoscopic versus open partial nephrectomy. Southeastern Section of the American Urological Association, March 19, 2011. New Orleans, Louisiana.
58. Selph JP, Langston J, Manvar A, Ferguson J, Smith A, Nielsen M, Wallen E, Pruthi R. Re-secting T1 bladder tumors: Single-institution analysis in a modern cohort of patients. Southeastern Section of the American Urological Associations, March 19, 2011. New Orleans, Louisiana.
59. Selph JP, Langston J, Martin A, Smith A, Sawh S, Raynor M, Nielsen M, Wallen E, Castle E, Pruthi R. Oncologic outcomes for node-positive patients undergoing robotic radical cystectomy. Southeastern Section of the American Urological Association, March 19, 2011. New Orleans, Louisiana.
60. Langston J, Selph JP, Ferguson J, Manvar A, Smith A, Raynor M, Nielsen M, Wallen E, Pruthi R. The evaluation of the learning curve associated with robotic radical cystectomy: Initial 100 cases. Southeastern Section of the American Urological Association, March 19, 2011. New Orleans, Louisiana.
61. Langston J, Selph JP, Ferguson J, Manvar A, Smith A, Raynor M, Nielsen M, Wallen E, Pruthi R. Robotic-assisted laparoscopic radical prostatectomy: Evaluation of the functional and oncologic learning curve. Southeastern Section of the American Urological Association, March 19, 2011. New Orleans, Louisiana.
62. Selph JP, Langston J, Martin A, Smith A, Sawh S, Raynor M, Nielsen M, Wallen E, Castle E, Pruthi R. Robotic radical cystectomy: Medium-term oncologic follow-up. Southeastern Section of the American Urological Association, March 19, 2011. New Orleans, Louisiana.
63. Selph JP, Langston J, Ferguson J, Manvar A, Smith A, Vyas S, Raynor M, Nielsen M, Wallen E, Pruthi R. Does robotic radical cystectomy for bladder cancer affect long-term health-related quality of life? Southeastern Section of the American Urological Association, March 19, 2011. New Orleans, Louisiana.
64. Langston J, Selph JP, Sawh S, Kim W, Godley P, Whang Y, Rathmell WK, Nielsen M, Wallen E, Pruthi R. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A phase II trial. Southeastern Section of the American Urological Association, March 18, 2011. New Orleans, Louisiana.
65. Selph JP, Langston J, Sawh S, Ferguson J, Manvar A, Smith A, Wallen E, Pruthi R, Lotan Y, Nielsen M. Risk-specific intensity of surveillance practices in non-muscle-invasive bladder cancer: Results from the BCAN/SUO/AUA/LUGPA Electronic Survey. Southeastern Section of the American Urological Association, March 18, 2011. New Orleans, Louisiana.

66. Selph JP, Langston J, Sawh S, Ferguson J, Manvar A, Smith A, Wallen E, Pruthi R, Lotan Y, Nielsen M. Patterns of utilization of urine-based markers in non-muscle-invasive bladder cancer: Results from BCAN/SUO/AUA/LUGPA Electronic Survey. Southeastern Section of the American Urological Association, March 18, 2011. New Orleans, Louisiana.
67. Langston J, Selph JP, Manvar A, Ferguson J, Sawh S, Smith A, Raynor M, Nielsen M, Carson C, Pruthi R. Clinical and pathologic differences between patients undergoing TURBT for newly-diagnosed versus recurrent bladder lesions detected by cystoscopy. Southeastern Section of the American Urological Association, March 18, 2011. New Orleans, Louisiana.
68. Selph JP, Langston J, Ferguson J, Manvar A, Smith A, Nielsen M, Wallen E, Pruthi R. The fate of men with incidental prostate cancer diagnosed at the time of radical cystectomy. Southeastern Section of the American Urological Association, March 17, 2011. New Orleans, Louisiana.
69. Langston J, Selph JP, Manvar A, Ferguson J, Smith A, Raynor M, Nielsen M, Wallen E, Pruthi R. HIFU and the internet: A quality control study of online information. Southeastern Section of the American Urological Association, March 17, 2011. New Orleans, Louisiana.
70. Pruthi R. Outcomes of robotic radical cystectomy and urinary diversion. American Urological Association Advanced Robotic Urologic Oncology, January 28, 2011. Celebration, Florida.
71. Pruthi R. Video: Robotic cystectomy and neobladder. American Urological Association Advanced Robotic Urologic Oncology, January 28, 2011. Celebration, Florida.
72. Pruthi R. Complications of robotic cystectomy and diversion. American Urological Association Advanced Robotic Urologic Oncology, January 28, 2011. Celebration, Florida.
73. Pruthi R. Learning robotic cystectomy: Recommendations for beginners. American Urological Association Advanced Robotic Urologic Oncology, January 28, 2011. Celebration, Florida.
74. Pruthi R. Video: Robotic anterior pelvic exenteration. American Urological Association Advanced Robotic Urologic Oncology, January 28, 2011. Celebration, Florida.
75. Pruthi R. Video: Robotic Intracorporeal urinary diversion. American Urological Association Advanced Robotic Urologic Oncology, January 28, 2011. Celebration, Florida.
76. Pruthi RS. Robotic Intracorporeal urinary diversion. IRUS National Meeting, January 14, 2011. Las Vegas, Nevada.

77. Rosenman JG, Chen RC, Hoffman LG, Chiu WK, Pruthi RS, Wallen EM, Kim WY, Rathmell WK, Godley PA, Whang YE. Phase 1 study of concurrent weekly docetaxel, androgen deprivation, and high-dose external beam radiation therapy (RT) for high-risk prostate cancer. American Society for Radiation Oncology, November 3, 2010. San Diego, California.
78. Pruthi RS. Robotic radical cystectomy for bladder cancer. Society of Pelvic Surgeons, September 17, 2010. Durham, North Carolina.
79. Pruthi RS. Robot assisted radical cystectomy: Oncologic outcomes and perspectives. Society of Urological Robotic Surgery presentation at the 28th World Congress, September 2, 2010. Chicago, Illinois.
80. Pruthi RS. Estrogen deficiency as an unintended side effect of androgen deprivation therapy. Indian AUA Annual Meeting, May 29, 2010, San Francisco, California.
81. McKim S, Simopoulos E, Raynor M, Smith A, Nielsen M, Wallen W, Pruthi R. Robotic cystectomy and the internet: Fact or fiction? American Urological Association, May 29 – June 3, 2010. San Francisco, California.
82. McKim S, Simopoulos E, Raynor M, Smith A, Nielsen M, Wallen W, Pruthi R. Preliminary experience with prostate-sparing cystectomy for urothelial carcinoma of the bladder. American Urological Association, May 29 – June 3, 2010. San Francisco, California.
83. Raynor M, McKim S, Simopoulos E, Smith A, Nielsen M, Wallen W, Pruthi R. Does obesity impact outcomes in patients undergoing robotic cystectomy for bladder cancer: a multi-institutional analysis. American Urological Association, May 29 – June 3, 2010. San Francisco, California.
84. Simopoulos E, McKim S, Raynor M, Smith A, Nielsen M, Wallen E, Pruthi R. The impact of race and gender in patients undergoing radical cystectomy for bladder cancer. American Urological Association, May 29 – June 3, 2010. San Francisco, California.
85. McKim S, Simopoulos E, Raynor M, Smith A, Nielsen M, Wallen E, Pruthi R. The impact of radical cystectomy on renal function: An analysis of variance based on age, gender, race, and diversion technique. American Urological Association, May 29 – June 3, 2010. San Francisco, California.
86. Raynor M, McKim S, Simopoulos E, Smith A, Nielsen M, Wallen E, Pruthi R. Multi-institutional analysis of robotic radical cystectomy for bladder cancer: Peri-operative outcomes in 227 patients. American Urological Association, May 29 – June 3, 2010. San Francisco, California.
87. Simopoulos E, McKim S, Raynor M, Smith A, Nielsen M, Wallen E, Pruthi R. Long-term follow-up of patients initially managed with active surveillance for solid renal masses. American Urological Association, May 29 – June 3, 2010. San Francisco, California.

88. Raynor M, McKim S, Simopoulos E, Smith A, Nielsen M, Wallen E, Pruthi R. Feasibility and outcomes of robotic-assisted laparoscopic radical cystectomy for bladder cancer in the elderly. American Urological Association, May 29 – June 3, 2010. San Francisco, California.
89. McKim S, Simopoulos E, Raynor M, Smith A, Nielsen M, Wallen E, Pruthi R. Robotic-assisted laparoscopic intracorporeal urinary diversion. American Urological Association, May 29 – June 3, 2010. San Francisco, California.
90. Pruthi RS. Estrogen deficiency as an unintended consequence of ADT. Indian American Urological Association, May 29, 2010. San Francisco, California.
91. Pruthi RS. Surgery and urinary reconstruction for muscle-invasive bladder cancer. Understanding Bladder Cancer – a Bladder Cancer Advocacy Network Patient Forum, Friday Center, May 15, 2010. Chapel Hill, North Carolina.
92. McKim S, Simopoulos E, Smith A, Nix J, Raynor M, Nielsen M, Wallen E, Pruthi R. Prospective, randomized trial of robotic versus open radical cystectomy for bladder cancer: peri-operative and pathological results. Southeastern Section of the American Urological Association, March 12, 2010. Miami Beach, Florida.
93. Raynor M, Smith A, Amling C, Busby JE, Castle E, Davis R, Thomas R, Nielsen M, Wallen E, Pruthi R. Complications associated with robotic radical cystectomy for bladder cancer: A multi-institutional analysis. Southeastern Section of the American Urological Association, March 12, 2010. Miami Beach, Florida.
94. McKim S, Simopoulos E, Smith A, Raynor M, Nielsen M, Wallen E, Pruthi R. Robotic-assisted laparoscopic intracorporeal urinary diversion. Southeastern Section of the American Urological Association, March 12, 2010. Miami Beach, Florida.
95. McKim S, Simopoulos E, Smith A, Raynor M, Nielsen M, Wallen E, Pruthi R. Feasibility and outcomes of robotic-assisted laparoscopic radical cystectomy for bladder cancer in the elderly. Southeastern Section of the American Urological Association, March 12, 2010. Miami Beach, Florida.
96. McKim S, Simopoulos E, Nielsen M, Wallen E, Pruthi R. Fast track program in patients undergoing radical cystectomy: Experience in 362 consecutive cases. Southeastern Section of the American Urological Association, March 12, 2010. Miami Beach, Florida.
97. Raynor M, Smith A, Amling C, Busby JE, Castle E, Davis R, Thomas R, Nielsen M, Wallen E, Pruthi R. Multi-institutional analysis of robotic radical cystectomy for bladder cancer: Peri-operative outcomes in 227 patients. Southeastern Section of the American Urological Association, March 12, 2010. Miami Beach, Florida.
98. Simopoulos E, McKim S, Dray E, Smith A, Nielsen M, Wallen E, Pruthi R. Does age affect presentation and outcomes in patients undergoing radical cystectomy for bladder cancer? Southeastern Section of the American Urological Association, March 12, 2010. Miami Beach, Florida.

99. Simopoulos E, McKim S, Rathmell K, William K, Godley P, Whang Y, Nielsen M, Wallen E, Pruthi R. A neoadjuvant clinical trial with sorafenib for patients with Stage II or greater renal cell carcinoma. Southeastern Section of the American Urological Association, March 11, 2010. Miami Beach, Florida.
100. Simopoulos E, McKim S, Waldorf B, Smith A, Nielsen M, Wallen E, Pruthi R. Long-term follow-up of patients initially managed with active surveillance for solid renal masses. Southeastern Section of the American Urological Association, March 11, 2010. Miami Beach, Florida.
101. Raynor M, Nielsen M, Wallen E, Pruthi R. Robotic-assisted laparoscopic intracorporeal urinary diversion. Video. Southeastern Section of the American Urological Association, March 11, 2010. Miami Beach, Florida.
102. Raynor M, Nielsen M, Wallen E, Pruthi R. Robotic-assisted approaches to partial cystectomy for benign and malignant disease of the bladder. Video. Southeastern Section of the American Urological Association, March 11, 2010. Miami Beach, Florida.
103. Pruthi RS. Expansion of Robotics in Urologic Oncology: Video of technique and summary of outcomes. 5th International Congress, Minimally Invasive Robotics Association, January 27, 2010. San Diego, California.
104. Pruthi RS. Extracorporeal and intracorporeal urinary diversion after robotic cystectomy. International Robotic Urology Symposium, January 16, 2010. Las Vegas, Nevada.
105. McKim S, Simopoulos E, Kim W, Godley P, Whang Y, Rathmell WK, Nielsen M, Wallen E, Pruthi RS. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a Phase II trial. Society of Urologic Oncology Annual Meeting, December 2 - 4, 2009. Bethesda, Maryland.
106. Simopoulos E, McKim S, Rathmell WK, Kim W, Godley P, Whang Y, Nielsen M, Wallen E, Pruthi RS. A neoadjuvant clinical trial with sorafenib for patients with Stage II or greater renal cell carcinoma. Society of Urologic Oncology Annual Meeting, December 2 - 4, 2009. Bethesda, Maryland.
107. Simopoulos E, McKim S, Waldorf B, Smith A, Nielsen M, Wallen E, Pruthi RS. Long-term follow up of patients initially managed with active surveillance for solid renal masses. Society of Urologic Oncology Annual Meeting, December 2 – 4, 2009. Bethesda, Maryland.
108. Simopoulos E, McKim S, Lavien G, Smith A, Nielsen M, Wallen E, Pruthi RS. Elimination of bowel preparation in patients undergoing cystectomy and urinary diversion. Society of Urologic Oncology Annual Meeting, December 2 – 4, 2009. Bethesda, Maryland.
109. Raynor M, Smith A, Amling C, Busby JE, Castle E, Davis R, Thomas R, Nielsen M, Wallen E, Pruthi RS. Multi-institutional analysis of robotic radical cystectomy for bladder cancer: perioperative outcomes in 227 patients. Society of Urologic Oncology Annual Meeting, December 2 – 4, 2009. Bethesda, Maryland.

110. McKim S, Simopoulos E, Nielsen M, Wallen E, Pruthi RS. Fast track program in patients undergoing radical cystectomy: experience in 362 consecutive cases. Society of Urologic Oncology Annual Meeting, December 2 – 4, 2009. Bethesda, Maryland.
111. McKim S, Simopoulos E, Dray E, Smith A, Nielsen M, Kim W, Wallen E, Pruthi RS. Use and outcomes of adjuvant chemotherapy in PT3-4 or node positive bladder cancer: analysis of a modern surgical cohort. Society of Urologic Oncology Annual Meeting, December 2 – 4, 2009. Bethesda, Maryland.
112. Hayn M, Hellenthal N, Hussain A, Andrews P, Carpentier P, Castle E, Dasgupta P, Davis R, Khan S, Kibel A, Kim H, Manoharan M, Menon M, Mottrie A, Ornstein D, Peabody J, Pruthi R, Redorta J, Richstone L, Schanne F, Stricker H, Wiklund P, Wilding G, Guru K. Does prior robot-assisted prostatectomy experience affect outcomes at robot-assisted radical cystectomy? Results from the International Robotic Cystectomy Consortium. Society of Urologic Oncology Annual Meeting, December 4, 2009. Bethesda, Maryland.
113. Hellenthal N, Hussain A, Andrews P, Carpentier P, Castle E, Dasgupta P, David R, Khan S, Kibel A, Kim H, Manoharan M, Menon M, Mottrie A, Ornstein D, Peabody J, Pruthi R, Redorta J, Richstone L, Schanne F, Stricker H, Wiklund P, Wilding G, Guru K. Lymphadenectomy at the time of robotic-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Society of Urologic Oncology Annual Meeting, December 4, 2009. Bethesda, Maryland.
114. Hellenthal N, Hussain A, Andrews P, Carpentier P, Castle E, Dasgupta P, Davis R, Khan S, Kibel A, Kim H, Manoharan M, Menon M, Mottrie A, Ornstein D, Peabody J, Pruthi R, Redorta J, Richstone L, Schanne F, Stricker H, Wiklund P, Wilding G, Guru K. Status of surgical margins after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Society of Urologic Oncology Annual Meeting, December 4, 2009. Bethesda, Maryland.
115. Pruthi RS. Management of recurrent superficial bladder cancer. Emory University, Advances in Urology 2009, December 4, 2009. Atlanta, Georgia.
116. Pruthi RS. Robotic-assisted cystectomy. Emory University, Advances in Urology 2009, December 4, 2009. Atlanta, Georgia.
117. Pruthi RS, Smith A, Wallen E. Robotic-assisted laparoscopic radical cystectomy: evaluation of the learning curve. American College of Surgeons, October 13, 2009. Chicago, Illinois.
118. Nielsen M, Kurpad R, Wallen E, Pruthi R. Robotic-assisted laparoscopic pelvic lymphadenectomy. American College of Surgeons, October 13, 2009. Chicago, Illinois.
119. Pruthi RS, Lentz AC, Sand M, Kouba E, Wallen EM. Impact of marital status in patients undergoing radical cystectomy for bladder cancer. American College of Surgeons, October 12, 2009. Chicago, Illinois.

120. Kurpad R, Kim W, Rathmell WK, Godley P, Whang Y, Fielding J, Smith L, Pettiford A, Schultz H, Nielsen M, Wallen E, Pruthi R. The impact of a multidisciplinary approach in the management of urologic malignancies: does it influence diagnostic and treatment decisions? American College of Surgeons, October 12, 2009. Chicago, Illinois.
121. Smith A, Coward M, Lal A, Kurpad R, Nielsen M, Wallen E, Pruthi RS. Cost analysis of robotic-assisted laparoscopic radical cystectomy for bladder cancer. American College of Surgeons, October 12, 2009. Chicago, Illinois.
122. Smith A, Coward M, Kim W, Grigson G, Kurpad R, Nielsen M, Wallen E, Pruthi RS. A Phase II study of neoadjuvant erlotinib (Tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy: preliminary results. American College of Surgeons, October 12, 2009. Chicago, Illinois.
123. Coward M, Simham J, Carson C, Pruthi RS. Racial differences in prostate-specific antigen in hypogonadal men treated with testosterone replacement therapy. American College of Surgeons, October 12, 2009. Chicago, Illinois.
124. Pruthi RS. Modern approaches to the treatment of muscle-invasive bladder cancer. American College of Surgeons, October 12, 2009. Chicago, Illinois.
125. Pruthi RS. The impact of estrogen deficiency in the male secondary to hormonal therapy for prostate cancer. New England Section of the American Urological Association, September 25, 2009. Washington, DC.
126. Smith A, Coward M, Kelly D, Kurpad R, Nielsen M, Wallen E, Pruthi RS. An analysis of the impact of race on bladder cancer treatment and mortality. American Urological Association, April 2009. Chicago, Illinois.
127. Johnson D, Kelly D, Smith A, Coward M, Pruthi RS, Wallen E. Impact of hospital type on surgical treatment for kidney cancer: recent trends. American Urological Association, April 2009. Chicago, Illinois.
128. Wallen E, Brannon AR, Pruthi RS, Reddy A, Seiler M, Ganeson S, Bhanot G, Rathmell WK. Distinct molecular subtypes of clear cell renal cell carcinoma identified by simplified mRNA profiling predicts clinical outcome. American Urological Association, April 2009. Chicago, Illinois.
129. Coward M, Smith A, Belsante J, Kurpad R, Schultz H, Nix J, Wallen E, Pruthi RS. Clinical outcomes of a stapled ileal neobladder after radical cystectomy for bladder cancer. American Urological Association, April 2009. Chicago, Illinois.
130. Nix J, Coward M, Smith A, Kurpad R, Nielsen M, Wallen E, Pruthi RS. Feasibility and outcomes of robotic-assisted laparoscopic radical cystectomy for bladder cancer in the elderly. American Urological Association, April 2009. Chicago, Illinois.
131. Coward M, Smith A, Kurpad, Nix J, Schultz H, Nielsen M, Wallen E, Pruthi RS. Robotic-assisted laparoscopic radical cystectomy for bladder cancer: perioperative outcomes in 85 patients and comparison an open cohort. American Urological Association, April 2009. Chicago, Illinois.

132. Nix J, Coward M, Smith A, Kurpad R, Schultz H, Nielsen M, Wallen E, Pruthi RS. Prospective randomized trial of open versus robotic-assisted laparoscopic radical cystectomy for bladder cancer: interim results. American Urological Association, April 2009. Chicago, Illinois.
133. Smith A, Coward M, Lal A, Kurpad R, Nix J, Nielsen M, Wallen E, Pruthi RS. Analgesic use in open versus robotic-assisted laparoscopic radical prostatectomy. American Urological Association, April 2009. Chicago, Illinois.
134. Smith A, Coward M, Lal A, Kurpad R, Nix J, Nielsen M, Wallen E, Pruthi RS. Analgesic use in men undergoing robotic-assisted laparoscopic radical prostatectomy: a detailed analysis of demographic, clinical and operative influences. American Urological Association, April 2009. Chicago, Illinois.
135. Smith A, Coward M, Doak H, Kurpad R, Nix J, Nielsen M, Wallen E, Pruthi RS. Outcomes and implications of follow-up biopsies of men on active surveillance for low-risk prostate cancer. American Urological Association, April 2009. Chicago, Illinois.
136. Coward M, Smith A, Kurpad R, Nielsen M, Wallen E, Pruthi RS. Poster: Achieving complete success after robotic radical prostatectomy: is the trifecta in reach? Southeastern Section of the American Urological Association, March 29, 2009. Mobile, Alabama.
137. Coward M, Smith A, Kurpad R, Shingleton WB, Nielsen M, Wallen E, Pruthi RS. Poster: Robotic-assisted laparoscopic radical cystectomy: evaluation of the learning curve. Southeastern Section of the American Urological Association, March 29, 2009. Mobile Alabama.
138. Coward M, Smith A, Kurpad R, Nielsen M, Wallen E, Pruthi RS. Poster: Impact of obesity and adiposity on outcomes of patients undergoing radical cystectomy for bladder cancer. Southeastern Section of the American Urological Association, March 29, 2009. Mobile, Alabama.
139. Smith A, Coward M, Kurpad R, Nielsen M, Wallen E. Pruthi RS. Poster: The impact of a multidisciplinary approach to the management of bladder cancer. Southeastern Section of the American Urological Association, March 29, 2009.
140. Coward M, Smith A, Kurpad R, Nielsen M, Wallen E, and Pruthi RS. Impact of obesity on operative, pathologic and functional outcomes after robotic-assisted laparoscopic radical prostatectomy. Southeastern Section of the American Urological Association, March 27, 2009. Mobile, Alabama.
141. Johnson D, Kelly D, Smith A, Coward M, Pruthi RS, Wallen E. Impact of hospital type on surgical treatment for kidney cancer: recent trends. Southeastern Section of the American Urological Association, March 27, 2009. Mobile, Alabama.
142. Coward M, Smith A, Kurpad R, Nielsen M, Wallen E, Pruthi RS. Robotic-assisted laparoscopic radical cystectomy for bladder cancer: experience in 85 patients and comparison to an open cohort. Southeastern Section of the American Urological Association, March 27, 2009. Mobile, Alabama.

143. Smith A, Coward M, Lal A, Kurpad R, Nielsen M, Wallen E, Pruthi RS. Cost analysis of robotic-assisted laparoscopic radical cystectomy for bladder cancer. Southeastern Section of the American Urological Association, March 27, 2009. Mobile, Alabama.
144. Smith A, Coward M, Kim W, Grigson G, Kurpad R, Wallen E, Nielsen M, Pruthi RS. A Phase II study of neoadjuvant erlotinib (Tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy: preliminary results. Southeastern Section of the American Urological Association, March 27, 2009. Mobile, Alabama.
145. Kelly D, Smith A, Coward M, Kurpad R, Nielsen M, Wallen E, Pruthi RS. An analysis of the impact of race on bladder cancer treatment and mortality. Southeastern Section of the American Urological Association, March 27, 2009. Mobile, Alabama.
146. Belsante J, Coward M, Smith A, Kurpad R, Wallen E, Pruthi RS. Preliminary experience with prostate-sparing cystectomy for urothelial carcinoma of the bladder. Southeastern Section of the American Urological Association, March 27, 2009. Mobile, Alabama.
147. Smith A, Coward M, Nielsen, Wallen E, Pruthi RS. Video: Robotic-assisted laparoscopic anterior pelvic exenteration for bladder cancer in the female. Southeastern Section of the American Urological Association, March 27, 2009. Mobile, Alabam
148. Doak H, Smith A, Coward M, Kurpad R, Nielsen M, Wallen E, Pruthi RS. Outcomes and implications of follow-up biopsies of men on active surveillance for low-risk prostate cancer. Southeastern Section of the American Urological Association, March 26, 2009. Mobile, Alabama.
149. Coward M, Smith, A, Nielsen M, Wallen E, Pruthi RS. Video: Robotic-assisted laparoscopic pelvic lymphadenectomy. Southeastern Section of the American Urological Association, March 26, 2009. Mobile, Alabama.
150. Pruthi R, Kim W, Rathmell K, Whang Y, Godley P, Wallen E, Kurpad R, Smith A. The impact of a multidisciplinary approach in the management of urologic malignancies: does it influence diagnostic and treatment decisions? American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium, February 26 – 28, 2009. Orlando, Florida.
151. Pruthi R, Kim W, Kurpad R, Smith A, Heathcote S, Rathmell K, Whang Y, Godley P, Wallen E. A Phase II study of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: preliminary clinical results. American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium, February 26 – 28, 2009. Orlando, Florida.
152. Pruthi R, Kim W, Rathmell K, Whang Y, Godley P, Wallen E, Kurpad R, Smith A. The impact of a multidisciplinary approach to the management of bladder cancer. American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium, February 26 – 28, 2009. Orlando, Florida.

153. Doak H, Smith A, Coward M, Kurpad R, Nielsen M, Wallen E, Pruthi R. Outcomes and implications of follow up biopsies of men on active surveillance for low risk prostate cancer. Society of Urologic Oncology, December 4 – 5, 2008. Bethesda, Maryland.
154. Smith A, Coward M, Kelly D, Nielsen M, Wallen E, Pruthi R. Evaluation of the incidence of a second urologic malignancy (bladder cancer and kidney cancer) in men with a diagnosis of prostate cancer. Society of Urologic Oncology, December 4 – 5, 2008. Bethesda, Maryland.
155. Smith A, Coward M, Kurpad R, Nielsen M, Wallen E, Pruthi R. The impact of a multidisciplinary approach in the management of urologic malignancies: does it influence diagnostic and treatment decisions? Society of Urologic Oncology, December 4 – 5, 2008. Bethesda, Maryland.
156. Smith A, Coward, Kelly D, Kurpad R, Nielsen M, Wallen E, Pruthi R. An analysis of the impact of race on bladder cancer treatment and mortality. Society of Urologic Oncology, December 4 – 5, 2008. Bethesda, Maryland.
157. Coward M, Smith A, Kurpad R, Nielsen M, Wallen E, Pruthi R. Robotic-assisted laparoscopic radical cystectomy: medium-term clinical and oncologic follow up. Society of Urologic Oncology, December 4 – 5, 2008. Bethesda, Maryland.
158. Coward M, Smith A, Kurpad R, Nielsen M, Wallen E, Pruthi R. Robotic-assisted laparoscopic anterior pelvic exenteration for bladder cancer in the female. Society of Urologic Oncology, December 4 – 5, 2008. Bethesda, Maryland.
159. Coward M, Smith A, Kurpad R, Nielsen M, Wallen E, Pruthi R. Impact of obesity and adiposity on outcomes of patients undergoing radical cystectomy for bladder cancer. Society of Urologic Oncology, December 4 – 5, 2008. Bethesda, Maryland.
160. Coward M, Smith A, Pearson M, Kurpad R, Kim W, Nielsen M, Wallen E, Pruthi R. A Phase II study of neoadjuvant erlotinib (tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy: preliminary results. Society of Urologic Oncology, December 4 – 5, 2008. Bethesda, Maryland.
161. Smith A, Coward M, Kurpad R, Wallen E, Pruthi R. Robotic-assisted laparoscopic radical cystectomy: evaluation of the learning curve. World Congress of Endourology, December 2, 2008. Shanghai, China.
162. Smith A, Coward M, Kurpad R, Wallen E, Pruthi R. Robotic-assisted laparoscopic radical cystectomy for bladder cancer: experience in 71 patients and comparison to an open cohort. World Congress of Endourology, December 2, 2008. Shanghai, China.
163. Smith A, Coward M, Kurpad R, Wallen E, Pruthi R. Robotic-assisted laparoscopic radical cystectomy: short-term clinical follow up. World Congress of Endourology, December 2, 2008. Shanghai, China.
164. Smith A, Coward M, Kurpad R, Wallen E, Pruthi R. Cost analysis of robotic-assisted laparoscopic radical cystectomy for bladder cancer. World Congress of Endourology, December 2, 2008. Shanghai, China.

165. Smith A, Coward M, Kurpad R, Wallen E, Pruthi R. The impact of bladder neck sparing modification on surgical and functional outcomes after robotic-assisted laparoscopic radical prostatectomy. World Congress of Endourology, December 2, 2008. Shanghai, China.
166. Smith A, Coward M, Kurpad R, Wallen E, Pruthi R. Robotic-assisted laparoscopic pelvic lymphadenectomy. World Congress of Endourology, December 1, 2008. Shanghai, China.
167. Smith A, Coward M, Kurpad R, Wallen E, Pruthi R. Robotic-assisted laparoscopic anterior pelvic exenteration for bladder cancer in the female. World Congress of Endourology, December 1, 2008. Shanghai, China.
168. Smith A, Coward M, Kurpad R, Wallen E, Pruthi R. Impact of race on operative, pathologic and functional outcomes after robotic-assisted laparoscopic radical prostatectomy. World Congress of Endourology, December 1, 2008. Shanghai, China.
169. Smith A, Coward M, Kurpad R, Wallen E, Pruthi R. Impact of obesity on operative, pathologic and functional outcomes after robotic-assisted laparoscopic radical prostatectomy. World Congress of Endourology, November 30, 2008. Shanghai, China.
170. Smith A, Coward M, Kurpad R, Wallen E, Pruthi R. Does an enlarged intravesical median lobe impact surgical and functional outcomes after robotic-assisted laparoscopic radical prostatectomy? World Congress of Endourology, November 30, 2008. Shanghai, China.
171. Smith A, Coward M, Kurpad R, Wallen E, Pruthi R. Does prior laparoscopic hernia repair impact surgical and functional outcomes after robotic-assisted laparoscopic radical prostatectomy? World Congress of Endourology, November 30, 2008. Shanghai, China.
172. Kouba E and Pruthi RS. Thomas Edison and the X-ray: Collaboration between industry and academia and effects on the evolution of urology. 4th International Congress on the History of Urology, November 8, 2008. Linthicum, Maryland.
173. Pruthi R.S. and Wallen E. The Impact of Bladder Neck-Sparing Modification on Outcomes after Robotic-Assisted Laparoscopic Radical Prostatectomy. American College of Surgeons, October 13, 2008. San Francisco, California.
174. Pruthi R.S. and Wallen E. Robotic-Assisted Laparoscopic Anterior Pelvic Exenteration for Bladder Cancer in the Female: Technique and Outcomes. American College of Surgeons, October 13, 2008. San Francisco, California.
175. Nix J., Pearson M., Kouba E., Wallen E., Pruthi R.S. Robotic-assisted laparoscopic radical cystectomy. American College of Surgeons, October 13, 2008. San Francisco, California.
176. Pearson M., Nix J., Kouba E., Wallen E., Pruthi R.S. Relationship of obesity and incidental prostate cancer detection in men undergoing radical cystoprostatectomy for

- bladder cancer. American College of Surgeons, October 13, 2008. San Francisco, California.
177. Pearson M., Nix J., Kim W., Grigson G., Wallen E., Pruthi R.S. A Phase II Study of neoadjuvant erlotinib (Tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy. American Society of Clinical Oncology. June 6, 2008. Chicago, Illinois.
 178. Pearson, M., Nix J., McKim S., Wallen E., Pruthi R.S. Partial cystectomy for bladder cancer: analysis of recent trends in its use and misuse. American Urological Association. May 20, 2008. Orlando, Florida.
 179. Pearson M., Nix J., Wallen E., Pruthi R.S. Robotic-assisted laparoscopic radical cystectomy: evaluation of the learning curve. American Urological Association. May 19, 2008. Orlando, Florida.
 180. Pearson M., Nix J., Wallen E., Pruthi R.S. Robotic-assisted laparoscopic versus open radical cystectomy: comparisons of a simultaneous experience. American Urological Association. May 19, 2008. Orlando, Florida.
 181. Pearson M., Nix J., Kouba E., Smith A., Wallen E., Pruthi R.S. Characterization of pT3A renal carcinoma in tumors less than 4.0 cm in size. American Urological Association. May 19, 2008. Orlando, Florida.
 182. Khurshid G., Pruthi R.S., Zubair B., Wallen E., Muhltaler F., Mohler J., Strickler H., Kim H., Wiklund P., Peabody J., Menon M. International Robot-assisted Cystectomy Consortium (IRCC): Immediate oncologic results after one hundred and sixty two cases. American Urological Association. May 19, 2008. Orlando, Florida.
 183. Pearson M., Nix J., Amin C., Rathmell K., Whang Y., Godley P., Pruthi R.S., Wallen E. Effect of neoadjuvant tyrosine kinase inhibitors on patients undergoing radical nephrectomy. American Urological Association. May 18, 2008. Orlando, Florida.
 184. Pearson M., Nix J., McKim S., Wallen E., Pruthi R.S. Trends of length of stay in patients undergoing radical cystectomy. American Urological Association. May 18, 2008. Orlando, Florida.
 185. Pearson M., Nix J., Kim W., Grigson G., Wallen E., Pruthi R.S. A Phase II Study of neoadjuvant erlotinib (Tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy: preliminary results. American Urological Association. May 18, 2008. Orlando, Florida.
 186. Pearson M., Nix J., McKim S., Wallen E., Pruthi R.S. Trends of cystectomy use in octogenarians with bladder cancer. American Urological Association. May 17, 2008, Orlando, Florida.
 187. Pruthi R.S. Professional Pathways Career Choices. Young Urologists Forum. Southeast Section of the American Urological Association. March 8, 2008. San Diego, California.

188. Pruthi R.S. Moderator, Bladder Cancer Podium Session. Southeast Section of the American Urological Association. March 8, 2008. San Francisco, California.
189. Nix J., Pearson M., Kouba E., Wallen E., Pruthi R.S. Clinical usefulness of serum CA 125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Southeast Section of the American Urological Association. March 8, 2008. San Diego, California.
190. Nix J., Pearson M., Wallen E., Pruthi R.S. The impact of bladder neck sparing modification on surgical and functional outcomes after robotic-assisted laparoscopic radical prostatectomy? Southeast Section of the American Urological Association. March 8, 2008. San Diego, California.
191. Pearson M., Nix J., Amin C., Rathmell K., Whang Y., Wallen E., Pruthi R.S. Effect of neoadjuvant tyrosine kinase inhibitors on patients undergoing radical nephrectomy. Southeast Section of the American Urological Association. March 7, 2008. San Diego, California.
192. Wallen E., Pruthi R.S. Video: Bladder neck preservation during robotic-assisted laparoscopic prostatectomy. Southeast Section of the American Urological Association. March 7, 2008. San Diego, California.
193. Nix J., Pearson M., Wallen E., Pruthi R.S. Impact of obesity on operative, pathologic, and functional outcomes after robotic-assisted laparoscopic radical prostatectomy. Southeast Section of the American Urological Association. March 7, 2008. San Diego, California.
194. Pearson M., Nix J., McKim S., Wallen E., Pruthi R.S. Partial cystectomy for bladder cancer: analysis of recent trends in its use and misuse. Southeast Section of the American Urological Association. March 6, 2008. San Diego, California.
195. Pruthi R.S. Phase II trial of Lapatinib in hormone refractory prostate cancer. American Society of Clinical Oncology (ASCO) - 2008 Genitourinary Cancers Symposium - A Multidisciplinary Approach. February 15, 2008. San Francisco, California.
196. Pearson M., Nix J., Amin C., Rathmell K., Whang Y., Godley P., Pruthi R.S. Effect of neoadjuvant tyrosine kinase inhibitors on patients undergoing radical nephrectomy. American Society of Clinical Oncology (ASCO) - 2008 Genitourinary Cancers Symposium - A Multidisciplinary Approach. February 14, 2008. San Francisco, California.
197. Nix J., Pearson M., Wallen EM, Pruthi R.S. Trends in cystectomy use in octogenarians with bladder cancer. Society of Urologic Oncology. December 1, 2007. Bethesda, Maryland.
198. Pearson M., Nix J., Wallen EM, Pruthi R.S. The impact of bladder neck sparing modification on surgical and functional outcomes after robotic-assisted laparoscopic radical prostatectomy. Society of Urologic Oncology. December 1, 2007. Bethesda, Maryland.

199. Pearson M., Nix J., Kim W., Grigson G., Wallen EM, Pruthi R.S. A Phase II Study of neoadjuvant erlotinib (Tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy: preliminary results. Society of Urologic Oncology. December 1, 2007. Bethesda, Maryland.
200. Rathmell, Amin C., Cowey C., Pruthi R.S., Wallen E., Khandani A. Neoadjuvant therapy with sorfenib for locally advanced renal cell carcinoma (RCC). AACR Molecular Targets Meeting. October 2007. San Francisco, California.
201. Rathmell K., Amin C., Pruthi R.S., Wallen E. Neoadjuvant clinical trials: a new twist on an old study. AACR Molecular Targets Meeting. October 2007. San Francisco, California.
202. Lentz A, Sands M, Kouba E, Wallen E, Pruthi R.S. Clinical Usefulness Of Serum Ca 125 Levels In Patients Undergoing Radical Cystectomy For Transitional Cell Carcinoma Of The Bladder. American College of Surgeons, October 9, 2007. New Orleans, Louisiana.
203. Miller J., Swords K., Carson CC, Lavelle J., Wallen E., Pruthi R.S. Diagnostic Rates And Other Outcomes Based On Initial Versus Repeat Biopsy In A Cohort Of Men Undergoing An Modern Biopsy (10-12 Core) Scheme. American College of Surgeons, October 9, 2007. New Orleans, Louisiana.
204. Miller J, Bhalani V, Baldwin N, Kouba E, Wallen E, Pruthi R.S. Expectant management of patients with low-risk superficial bladder cancer. American Urological Association, May 22, 2007, Anaheim, California.
205. Miller J, Smith A, Gunn K, Kouba E, Wallen E, Pruthi R.S. Impact of surgical treatment of renal carcinoma on renal function and blood pressure: A race- and age-dependent association. American Urological Association, May 22, 2007, Anaheim, California.
206. Miller J, Smith A, Kouba E, Wallen E, Pruthi R.S. Gender-dependent associations between body composition in patients with renal cell carcinoma (RCC). American Urological Association, May 21, 2007, Anaheim, California.
207. Miller J, Smith A, Kouba E, Wallen E, Pruthi R.S. Prospective evaluation of short-term impact and recovery of health-related quality of life (HRQOL) in men undergoing robotic-assisted laparoscopic radical prostatectomy vs open radical prostatectomy (ORP). American Urological Association, May 20, 2007, Anaheim, California.
208. Lentz A, Sands M, Kouba E, Wallen E, Pruthi R.S. A comparison of the Bricker versus Wallace ureteroileal anastomosis in patients undergoing urinary diversion for bladder cancer. American Urological Association, May 20, 2007, Anaheim, California.
209. Lentz A, Sands M, Kouba E, Wallen E, Pruthi R.S. Stomal complications in patients undergoing radical cystectomy and ileal conduit urinary diversion for bladder cancer. American Urological Association, May 20, 2007, Anaheim, California.

210. Lentz A, Sands M, Kouba E, Wallen E, Pruthi R.S. Impact of marital status in patients undergoing radical cystectomy for bladder cancer. American Urological Association, May 20, 2007, Anaheim, California.
211. Pruthi R.S., Wallen E., Robotic-assisted laparoscopic radical cystectomy (video). American Urological Association, Southeastern Section. March 10, 2007. Orlando, Florida.
212. Kouba E., Miller J., Wallen E., Pruthi R.S. Characterization of Acute Phase Inflammation in Men Undergoing Robotic-Assisted Laparoscopic Radical prostatectomy (RALRP). American Urological Association, Southeastern Section. March 10, 2007. Orlando, Florida.
213. Miller J., Anderson A., Fielding J., Kouba E., Wallen E., Pruthi R.S. Accuracy of MR and CT cross sectional imaging in the staging of invasive bladder cancer: a prospective study blinded to clinical outcome. American Urological Association, Southeastern Section. March 10, 2007. Orlando, Florida.
214. Miller J, Swords K, Carson CC, Lavelle J, Wallen E, Pruthi RS. Diagnostic rates and other outcomes based on initial versus repeat biopsy in a modern cohort of men undergoing an extended biopsy (10-12 core) scheme. American Urological Association, Southeastern Section. March 10, 2007. Orlando, Florida.
215. Miller J., Kouba E., Smith A., Wallen E., Pruthi R.S. Prospective evaluation of short-term impact and recovery of health-related quality of life (HRQOL) in men undergoing Robotic-assisted laparoscopic radical prostatectomy (RALRP) VS. open radical prostatectomy (ORP). American Urological Association, Southeastern Section. March 10, 2007. Orlando, Florida.
216. Lentz A, Smith A, Kouba E, Wallen E, Pruthi RS. Impact of surgical treatment of renal carcinoma on renal function and blood pressure: a race- and age-dependent association. American Urological Association, Southeastern Section, March 10, 2007. Orlando, Florida.
217. Lentz A, Smith A, Kouba E, Wallen E, Pruthi RS. Gender dependent associations between body composition in patients with renal cell carcinoma (RCC). American Urological Association, Southeastern Section, March 10, 2007. Orlando, Florida.
218. Miller J., Bhalani V., Wallen E., Pruthi R.S. Expectant management of patients with low-risk superficial bladder cancer. American Urological Association, Southeastern Section. March 10, 2007. Orlando, Florida.
219. Lentz A., Sands M., Kouba E., Wallen E., Pruthi R.S. Stomal complications in patients undergoing radical cystectomy and ileal conduit urinary diversion for bladder cancer. American Urological Association, Southeastern Section. March 10, 2007. Orlando, Florida.
220. Lentz A., Wallen E., Pruthi R.S. Robotic-assisted laparoscopic radical cystectomy: initial experience and operative outcomes. American Urological Association, Southeastern Section. March 10, 2007. Orlando, Florida.

221. Carson CC 3rd, Coward M., Simhan J., Pruthi R.S. Prostate cancer in hypogonadal men on testosterone replacement therapy. American Urological Association, Southeastern Section. March 8, 2007. Orlando, Florida.
222. Miller J., Kouba E., Smith A., Wallen E., Pruthi R.S. Prospective evaluation of short-term impact and recovery of health-related quality of life (HRQOL) in men undergoing Robotic-assisted laparoscopic radical prostatectomy (RALRP) VS. open radical prostatectomy (ORP). Society of Urologic Oncology. December 2, 2006. Bethesda, Maryland.
223. Lentz A., Wallen E., Pruthi R.S. Robotic-assisted laparoscopic radical cystectomy: initial experience and operative outcomes. Society of Urologic Oncology. December 2, 2006. Bethesda, Maryland.
224. Hickerson A., Kouba E., Wallen E., Pruthi R.S. The Impact of Race and Gender in Patients Undergoing Radical Cystectomy for Bladder Cancer. American College of Surgeons, October 10, 2006. Chicago, Illinois.
225. McRackan D, Kouba E., Smith A., Wallen E., Pruthi R.S. Expectant management of small renal masses: Does a delay in therapy pose a clinical or pathological risk to the patient? American College of Surgeons, October 10, 2006. Chicago, Illinois.
226. Wallen E, Pruthi RS. The burden of kidney cancer in America: the urologic diseases of America project. American Urological Association. May 22, 2006, Atlanta, Georgia.
227. Hubbard JS, Stefaniak H, Moliterno J, Wallen E, Pruthi RS. Incidental finding of prostate cancer at cystoprostatectomy: changes in incidence in the PSA era. American Urological Association. May 21, 2006. Atlanta, Georgia.
228. McRackan D, Kouba E, Smith A, Wallen E, Pruthi RS. Expectant management of small renal masses: does a delay in therapy pose a clinical or pathological risk to the patient? American Urological Association. May 21, 2006. Atlanta, Georgia.
229. Hickerson A., Pruthi R.S., Wallen E.: Laparoscopic retroperitoneal lymph node dissection for low-stage testicular cancer: challenges and benefits. American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico.
230. McRackan D, Kouba E., Wallen E., Pruthi R.S. Recent experience of surgical management of renal masses: the evolution of laparoscopic approaches in clinical practice. American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico.
231. Hickerson A., Kouba E., Wallen E., Pruthi R.S.: Evaluation of the routine use of metocloperamide in patients undergoing radical cystectomy and urinary diversion. American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico.

232. Thomasch J., Kouba E., Hickerson A., Wallen E., Pruthi R.S Impact of Race on time to androgen independence and subsequent biochemical progression in men with advanced prostate cancer. American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico.
233. McRackan D, Evans A., Carson C., Wallen E., Michell P., Pruthi R.S An evaluation of prostate cancer knowledge in patients with prostate cancer in patients with prostate cancer and their partners. American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico.
234. McRackan D, Evans A., Carson C., Wallen E., Michell P., Pruthi R.S An evaluation of prostate cancer knowledge in patients with prostate cancer: impact of demographic and socioeconomic variables. American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico.
235. Hickerson A., Leese P., Moore D., Wallen E., Mohler J., Pruthi R.S.: Impact of race on treatment selection and disease progression in men who choose observation for clinically-localized prostate cancer. American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico.
236. Hickerson A, Leese P, Moore D, Wallen E, Mohler J, Pruthi RS. Watchful waiting for patients with locally-advanced and node-positive prostate cancer: biochemical and clinical outcomes. American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico.
237. Stefaniak H, Carson CC, Pruthi RS, Wallen E. Tadalafil therapy beginning on postoperative day one preserves potency in men undergoing radical prostatectomy - preliminary one-year results. American Urological Association, Southeastern Section. March 2, 2006, San Juan, Puerto Rico.
238. Wallen E, Pruthi RS. The burden of kidney cancer in America: the urologic disease of America project. American Urological Association, Southeastern Section. March 2, 2006, San Juan, Puerto Rico.
239. McRackan D, Kouba E., Smith A., Wallen E., Pruthi R.S Expectant management of small renal masses: Does a delay in therapy pose a clinical or pathological risk to the patient? American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico.
240. Thomasch J., Kouba E., Hickerson A., Wallen E., Pruthi R.S Impact of Race on time to androgen independence and subsequent biochemical progression in men with advanced prostate cancer. Society of Urologic Oncology. December 2, 2005. Bethesda, Maryland.
241. Pruthi R.S., Carson C.C. COX-2 inhibitors in PSA recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Urologic Research Society, November 10, 2005. Boston Massachusetts.
242. Hubbard J.S., Derksen J.E., Moliterno J., Wallen E., Pruthi R.S. Hand Assisted Laparoscopic Nephrectomy for Large Renal Masses. American College of Surgeons, October 16, 2005. San Francisco, California.

243. Stefaniak H., Carson C.C., Pruthi R.S., Wallen E., Tadalafil therapy beginning on post-operative day one preserves potency in men undergoing radical prostatectomy. American College of Surgeons, October 16, 2005. San Francisco, California.
244. Hubbard J.S., Wallen E., Pruthi R.S. Prospective evaluation of short-term impact and recovery of health-related quality of life (HRQOL) in men undergoing radical prostatectomy (RP). American Urological Association, May 25, 2005. San Antonio, Texas.
245. Santa-Cruz R.S., Derksen J.E., Moliterno J., Wallen E., Pruthi R.S. Efficacy and Safety of En Bloc Ligation of the Renal Hilum at the time of Laparoscopic Nephrectomy: Review of 62 consecutive cases. American Urological Association, May 22, 2005. San Antonio, Texas.
246. Derksen J.E., Grigson G., Wallen E., Pruthi R.S., Phase II trial of celecoxib in PSA recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. American Urological Association. May 22, 2005. San Antonio, Texas.
247. Stefaniak H., Wallen E., Pruthi R.S. Neoadjuvant Docetaxel and Estramustine Followed by Radical Prostatectomy or Radiation Therapy for Patients with High-Risk Prostate Cancer. American Urological Association. May 21, 2005. San Antonio, Texas.
248. Stefaniak H., Carson C.C., Pruthi R.S., Wallen E., Tadalafil therapy beginning on post-operative day one preserves potency in men undergoing radical prostatectomy. American Urological Association, Southeastern Section. March 3, 2005. Charleston, South Carolina.
249. Santa-Cruz R.S., Derksen J.E., Moliterno J., Wallen E., Pruthi R.S. Efficacy and Safety of En Bloc Ligation of the Renal Hilum at the time of Laparoscopic Nephrectomy: Review of 62 consecutive cases. American Urological Association, Southeastern Section. March 5, 2005. Charleston, South Carolina.
250. Santa-Cruz R.S., Derksen J.E., Moliterno J., Wallen E., Pruthi R.S. Hand Assisted Laparoscopic Nephrectomy for Large Renal Masses. American Urological Association, Southeastern Section. March 5, 2005. Charleston, South Carolina.
251. Santa-Cruz R.S., Derksen J.E., Moliterno J., Wallen E., Pruthi R.S. Safe and effective application of laparoscopic partial nephrectomy for small renal masses: duplication of open principles and practices. American Urological Association, Southeastern Section. March 5, 2005. Charleston, South Carolina.
252. Derksen J.E., Grigson G., Wallen E., Pruthi R.S. Phase II trial of celecoxib in PSA recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. American Urological Association, Southeastern Section. March 5, 2005. Charleston, South Carolina.
253. Evans A., Derksen J.E., Moliterno J., Wallen E., Pruthi R.S. Complications and reasons for prolonged stay in patients undergoing radical cystectomy utilizing a perioperative pathway. American Urological Association, Southeastern Section. March 4, 2005. Charleston, South Carolina.

254. Evans A., Derksen J.E., Moliterno J., Wallen E., Pruthi R.S. Costs and surgical outcomes associated with radical cystectomy: changes over the past decade. American Urological Association, Southeastern Section. March 3, 2005. Charleston, South Carolina.
255. Stefaniak H., Wallen E., Pruthi R.S. The use of the COX-2 inhibitor celecoxib to reduce perioperative pain associated with radical retropubic prostatectomy (RRP). American Urological Association, Southeastern Section. March 3, 2005. Charleston, South Carolina.
256. Hubbard J.S., Wallen E., Pruthi R.S. Prospective evaluation of short-term impact and recovery of health-related quality of life (HRQOL) in men undergoing radical prostatectomy (RP). American Urological Association, Southeastern Section. March 3, 2005. Charleston, South Carolina.
257. Stefaniak H., Wallen E., Pruthi R.S. Neoadjuvant Docetaxel and Estramustine Followed by Radical Prostatectomy or Radiation Therapy for Patients with High-Risk Prostate Cancer. American Urological Association, Southeastern Section. March 3, 2005. Charleston, South Carolina.
258. Hubbard J.S., Stefaniak H., Moliterno J., Wallen E., Pruthi R.S. Incidental Finding of prostate cancer at cystoprostatectomy: changes in incidence in the PSA era. American Urological Association, Southeastern Section. March 3, 2005. Charleston, South Carolina.
259. Hubbard J.S., Stefaniak H., Moliterno J., Wallen E., Pruthi R.S., Incidental Finding of prostate cancer at cystoprostatectomy: changes in incidence in the PSA era. Society of Urologic Oncology. December 3, 2004. Bethesda, Maryland.
260. Stefaniak H., Wallen E., Pruthi R.S. Neoadjuvant Docetaxel and Estramustine Followed by Radical Prostatectomy or Radiation Therapy for Patients with High-Risk Prostate Cancer. Society of Urologic Oncology. December 3, 2004. Bethesda, Maryland.
261. Santa-Cruz R.S., Derksen J.E., Moliterno J., Wallen E., Pruthi R.S. Safe and effective application of laparoscopic partial nephrectomy for small renal masses: duplication of open principles and practices. Society of Urologic Oncology. December 3, 2004. Bethesda, Maryland.
262. Derksen J.E., Pruthi R.S., Phase II trial of celecoxib in PSA recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. American College of Surgeons. October 11, 2004. New Orleans, Louisiana.
263. McLaughlin S., Chun J., Richman M., Pruthi R.S. Potential role of initial incision of the lateral pelvic fascia, development of a perirectal pocket, and early ligation of the vascular pedicles in reducing positive margins during radical prostatectomy. American College of Surgeons. October 11, 2004. New Orleans, Louisiana.
264. Tornehl C., Kouba E., Wallen E., Pruthi R.S. Initial experience with fibrin tissue sealants during laparoscopic partial nephrectomy. American College of Surgeons. October 11, 2004. New Orleans, Louisiana.

265. Baggstrom MQ, Rosenman J, Pruthi R.S., Whang Y., Goyal L, Grigson G, Godley P. A phase II trial of neo-adjuvant docetaxel (D) and estramustine (E) in patients with high risk/locally advanced prostate cancer. American Society of Clinical Oncology. June 6, 2004. New Orleans, Louisiana.
266. Pruthi R.S., Derksen JE. A phase II trial of celecoxib in PSA recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. American Society of Clinical Oncology. June 6, 2004. New Orleans, Louisiana.
267. Kang, J., Pruthi, R.S. Comparison of grade and stage in African American and Caucasian patients with prostate cancer: evaluation of clinical, biopsy, and surgical pathology. American Urological Association, Chief Resident Meeting. May 13, 2004. San Francisco, California.
268. Tornehl C., Gaston K.E., Carson C.C, Wallen E., Pruthi R.S. Impact of Race, Age, Income, and Residence on Prostate Cancer (CaP) Knowledge, Screening Behavior, and Health Maintenance in Siblings of Patients with CaP American Urological Association. May 12, 2004. San Francisco, California.
269. Tornehl C., Kouba E., Wallen E., Pruthi R.S. Partial nephrectomy with fibrin glue repair: measurement of vascular and pelvicaliceal bond integrity in a live porcine animal model. American Urological Association. May 10, 2004. San Francisco, California.
270. McLaughlin S., Funkhouser W.K., Wallen E.M., Pruthi R.S. Expression of Cyclooxygenase-2 in human renal cell carcinoma. American Urological Association. May 10, 2004. San Francisco, California.
271. McLaughlin S., Shephard J., Wallen E.M., Pruthi R.S. Comparison of clinical and pathological staging in patients undergoing primary versus delayed radical cystectomy for bladder cancer. American Urological Association. May 9, 2004. San Francisco, California.
272. Tornehl C., Kouba E., Wallen E., Pruthi R.S. Initial experience with fibrin tissue sealants during laparoscopic partial nephrectomy. American Urological Association, Southeastern Section. March 25, 2004. Aruba.
273. Tornehl C., Kouba E., Wallen E., Pruthi R.S. Partial nephrectomy with fibrin glue repair: measurement of vascular and pelvicaliceal bond integrity in a live porcine animal model. American Urological Association, Southeastern Section. March 26, 2004. Aruba.
274. McLaughlin S., Chun J., Richman M., Pruthi R.S. Potential role of initial incision of the lateral pelvic fascia, development of a perirectal pocket, and early ligation of the vascular pedicles in reducing positive margins during radical prostatectomy. American Urological Association, Southeastern Section. March 28, 2004. Aruba.
275. McLaughlin S., Chun J., Richman M., Pruthi R.S. Reducing time to oral diet and hospital discharge in patients undergoing radical cystectomy. American Urological Association, Southeastern Section. March 26, 2004. Aruba.

276. McLaughlin S., Shephard J., Wallen E.M., Pruthi R.S. Comparison of clinical and pathological staging in patients undergoing primary versus delayed radical cystectomy for bladder cancer. American Urological Association, Southeastern Section. March 26, 2004. Aruba.
277. Hawke NA, Pruthi R.S., Funkhouser WK, Baldwin AS. Phosphorylated serine 536 as an indicator of NF(B activity in prostate cancer. Keystone Symposia. January 11, 2004. Colorado.
278. Gaston K., Lee K., Pruthi R.S. Impact of Race, Age, Income, and Residence on Prostate Cancer (CaP) Knowledge, Screening Behavior, and Health Maintenance in Siblings of Patients with CaP. Society of Urologic Oncology, December 5, 2003. Bethesda, Maryland.
279. Gaston K., Lee K., Pruthi R.S. Impact of a Sibling's Diagnosis of Prostate Cancer (CaP) on Prostate Cancer Knowledge, Screening Behavior, and other Health-related Activities. Society of Urologic Oncology, December 5, 2003. Bethesda, Maryland.
280. McLaughlin S., Wallen E.M., Pruthi R.S. Expression of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCCa). Society of Urologic Oncology, December 5, 2003. Bethesda, Maryland.
281. McLaughlin S., Shephard J., Wallen E.M., Pruthi R.S. Comparison of clinical and pathological staging in patients undergoing primary versus delayed radical cystectomy for bladder cancer. Society of Urologic Oncology, December 5, 2003. Bethesda, Maryland.
282. Derksen J.E., Pruthi R.S. The use of the COX-2 inhibitor celecoxib in PSA-recurrent prostate cancer (CaP) after radiation therapy or radical prostatectomy: 12 month follow-up. Society of Urologic Oncology, December 5, 2003. Bethesda, Maryland.
283. Gaston K., Lee K., Pruthi R.S. Impact of race, income, and residence on prostate cancer knowledge, screening behavior, and health maintenance in sibling of patients with prostate cancer. American College of Surgeons Clinical Congress, October 20, 2003. Chicago, Illinois.
284. Derksen J.E., Fitzsimmons N., Ornstein D., Pruthi R.S. Early urethral catheter removal after radical retropubic prostatectomy. American College of Surgeons Clinical Congress, October 20, 2003. Chicago, Illinois.
285. Pruthi R.S. COX-2 inhibitors in PSA-recurrent prostate cancer: a pilot study. Innovators in Urology International Meeting. Amsterdam, The Netherlands. June 6, 2003.
286. Moliterno J., Tenkhenekov S., Ornstein D., Pruthi R.S. Incidental Finding of Prostate Cancer at Cystoprostatectomy. American Urological Association. April 30, 2003. Chicago, Illinois.
287. Ornstein DK, Fusaro V., Ross S., Hitt BA, Grigson G, Bell HA, Pruthi R.S., Liotta LA, Petricoin EF. Analysis of serum proteomic profiles with Seldi-TOF and

- artificial intelligence pattern-based recognition can help determine the need for prostate biopsy. April 29, 2003. Chicago, Illinois.
288. Derksen J.E., Fitzsimmons N., Ornstein D., Pruthi R.S. Factors affecting length of stay after radical retropubic prostatectomy. American Urological Association, Southeastern Section. March 30, 2003. Savannah, Georgia.
289. Gaston K., Lee K., Pruthi R.S. The impact of a siblings diagnosis of prostate cancer on prostate cancer knowledge, screening behavior, and other health-related activities. American Urological Association, Southeastern Section. March 30, 2003. Savannah, Georgia.
290. Chun J., Pruthi R.S. The use of fibrin tissue sealants during laparoscopic partial nephrectomy. American Urological Association, Southeastern Section. March 28, 2003. Savannah, Georgia.
291. Moliterno J., Tenkhenekov S., Ornstein D., Pruthi R.S. Comparison of clinical and pathological staging of bladder cancer. American Urological Association, Southeastern Section. March 28, 2003. Savannah, Georgia.
292. Derksen J.E., Fitzsimmons N., Ornstein D., Pruthi R.S. Early urethral catheter removal after radical retropubic prostatectomy. American Urological Association, Southeastern Section. March 27, 2003. Savannah, Georgia.
293. Moliterno J, Evans A, Ornstein DK, Mohler JL, Pruthi R.S. Characterization of PSA doubling times in patients who have failed radical prostatectomy. American College of Surgeons Clinical Congress, October 8, 2002. San Francisco, California.
294. Gaston K, Pruthi, R.S. The use of erythropoietin in patients undergoing prostatectomy: effects on hematocrit, transfusion rates, and quality of life. American College of Surgeons Clinical Congress, October 8, 2002. San Francisco, California.
295. Derksen E., Pruthi, R.S. COX-2 inhibitors in PSA-recurrent prostate cancer: a pilot study. American Urological Association, May 25, 2002. Orlando, California.
296. Gaston K, Pruthi, R.S. Hand-assisted laparoscopic nephrectomy: prospective evaluation of the learning curve. American Urological Association, Southeastern Section. March 3, 2002. Naples, Florida.
297. Derksen E., Pruthi, R.S. COX-2 inhibitors in PSA-recurrent prostate cancer: a pilot study. American Urological Association, Southeastern Section. March 3, 2002. Naples, Florida.
298. Kang, J., Mohler, J.L., Maygarden S.J., Pruthi, R.S. Impact of positive biopsy location on final tumor extent and unfavorable pathological outcomes in prostate cancer. American Urological Association. June 6, 2001. Anaheim, California.
299. Kang, J., Mohler, J.L., Pruthi, R.S. Comparison of grade and stage in African American and Caucasian patients with prostate cancer: evaluation of clinical, biopsy, and surgical pathology. American Urological Association, Southeastern Section. April 1, 2001. New Orleans, Louisiana.

300. Kang, J., Mohler, J.L., Pruthi, R.S. Impact of positive apical biopsies on unfavorable pathological outcomes in prostate cancer . American Urological Association, Southeastern Section. April 1, 2001. New Orleans, Louisiana.
301. Kang, J., Mohler, J.L., Pruthi, R.S. Unilaterally-positive sextant biopsies useful for predicting final pathology . American Urological Association, Southeastern Section. April 1, 2001. New Orleans, Louisiana.
302. Pruthi, R.S., and Stamey, T.A. PSA doubling times and times to PSA recurrence in patients who fail radical prostatectomy. 24th Annual Northern California Residents Conference. May 3, 1997. San Francisco, California. (Winner, First Prize)
303. Pruthi, R.S., Tu, I-P, Johnstone, I., Stamey, T.A. PSA doubling times in patients who fail radical prostatectomy: correlation with histology of the primary cancer. American Urological Association. April 16, 1997. New Orleans, Louisiana.
304. Pruthi, R.S., Angell, S.A., Dubocq, F., Merguerian, P.A., Shortliffe, L.D. The use of renal parenchymal area in children with vesicoureteral reflux. American Academy of Pediatrics -- Section on Urology. October 27, 1996. Boston, Massachusetts.
305. Pruthi, R.S., and Stamey, T.A. The use of serum concentration techniques to enhance early detection of recurrent prostate cancer after radical prostatectomy. 23rd Annual Northern California Residents Conference. April 27, 1996. Sacramento, California. (Winner, Second Prize)
306. Pruthi, R.S., Angell S.A., Freiha, F.S. Papillary thyroid carcinoma found in the kidney. 22nd Annual Northern California Residents Conference. March 4, 1995. Stanford, California. (Winner, First Prize)
307. Pruthi, R.S., Farouk, M., Meyers, W.C. Somatostatin analogue inhibits hepatic regeneration. Clinical Congress of the American College of Surgeons. October 21, 1991. Chicago, Illinois.
308. Pruthi, R.S., Farouk, M., Meyers, W.C. The effect of octreotide on liver regeneration in the rat. 22nd Annual AOA Original Studies Symposium. March 28, 1991. Durham, North Carolina.

Videos

Pruthi RS, Stefaniak H, Wallen EM. Robot-assisted laparoscopic anterior pelvic exenteration for bladder cancer in women. *J of Endourology, Part B, Videourology*, 2007; DOI:10.1089/vid.209.056.

Pruthi RS, Wallen EM. Robotic-assisted laparoscopic radical cystoprostatectomy. *Surgery-in-Motion. European Urology*. February, 2008.

Pruthi RS, Wallen EM. Robotic-assisted laparoscopic radical cystoprostatectomy. *Intuitive Corporation*. January, 2008.

Chun J, Pruthi RS. Laparoscopic Partial Nephrectomy. Baxter Incorporated. April, 2003. 309.

Guidelines

'Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update' Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JS Jr, Schellhammer PF. American Urological Association. December, 2007, pp 1 -97.

Accepted

Cowey CL, Amin C, Pruthi RS, Wallen E, Nielsen M, Grigson G, Watkins C, Nance K, Crane J, Jalkut M, Kim W, Godley P, Whang Y, Field J, Rathmell WK. A neoadjuvant clinical trial with sorafenib for patients with Stage II or greater renal cell carcinoma. J of Clinical Oncology, (accepted)

Teaching Record

Course Director

UNC

Course Director, Third Annual Landes Symposium on the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 17-18, 2005. Chapel Hill, North Carolina.

Course Co-director, Complex Laparoscopic Surgery in Urology. University of North Carolina, Chapel Hill, North Carolina. February 13-14, 2005.

Course Director, Advances in the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. February 13-14, 2004.

Course Director, Symposium on the Multidisciplinary Advances in the Treatment of Prostate Cancer. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. February 1-2, 2003.

Course Co-Director Laparoscopic Renal Surgery. University of North Carolina, Chapel Hill, North Carolina. September 14-15, 2001.

Course Co-director, Laparoscopic Renal Surgery. University of North Carolina, Chapel Hill, North Carolina. June 13-14, 2001.

Local Course Director. Laparoscopic Renal Cryoablation: Live surgery telecast. University of North Carolina, Chapel Hill, North Carolina. November 28, 2000.

Outside UNC

Moderator. Bladder Cancer: Metastatic Disease/Staging. American Urological Association National Meeting, May 23, 2012. Atlanta, Georgia.

Moderator. Bladder Cancer: Therapeutic Advances. American College of Surgeons Clinical Congress, October 26, 2011, San Francisco, CA.

Course Director. Robotic Radical Cystectomy: Getting Started and Tips and Tricks from the Experts. American Urological Association National Meeting, May 15, 2011. Washington, DC.

Course Faculty. Live Surgery. Robot Assisted Radical Cystectomy and Extended Lymphadenectomy. American Urological Association National Meeting, May 14, 2011. Washington, DC.

Moderator: Session 1, American Urological Association National Meeting, May 14, 2011, Washington, DC.

Moderator: Urooncology Poster Session, Southeastern Section of the American Urological Association, March 19, 2011. New Orleans, Louisiana.

Moderator: Video: Robotic cystectomy and ileal conduit. American Urological Association Advanced Robotic Urologic Oncology, January 28, 2011. Celebration, Florida.

Moderator. Robotic Radical Cystectomy. IRUS National Meeting, January 13, 2011. Las Vegas, NV.

Moderator. Live Surgeries. Robotic Radical Prostatectomy. Robotic Adrenalectomy. Robotic Partial Nephrectomy. IRUS National Meeting, January 13, 2011. Las Vegas, NV.

Course Director: "Robotic Cystectomy Presentation". 28th World Congress, September 4, 2010. Chicago, Illinois.

Chair: Robotic/Bladder Poster Session. 28th World Congress, September 1, 2010, Chicago, Illinois.

Moderator: AUA Live Surgery Course "Robotic Radical Prostatectomy". American Urological Association Annual Meeting, May 29, 2010, San Francisco, California.

Moderator, Kidney Cancer. Indian American Urological Association, May 29, 2010. San Francisco, California.

Moderator, Prostate/Testis Cancer Poster Session. Southeastern Section of the American Urological Association, March 13, 2010. Miami Beach, Florida.

Co-Moderator. Urology. American College of Surgeons Annual Meeting, October 13, 2009. Chicago, Illinois.

Panelist. Urological Surgery. American College of Surgeons Annual Meeting, October 13, 2009. Chicago, Illinois.

Moderator. Urology and Reproductive Surgery II. American College of Surgeons Annual Meeting, October 13, 2009. Chicago, Illinois.

Course Director. Carcinoma of the Bladder: Advances in Management. American College of Surgeons Annual Meeting. October 12, 2009. Chicago, Illinois.

Moderator, Bladder Cancer Podium. Southeastern Section of the American Urological Association, March 27, 2009. Mobile, Alabama.

Director, 8th Annual North Carolina Residents Seminar. November 1, 2008. Greensboro, North Carolina.

Moderator/Course Director. ACS Course: Carcinoma of the Bladder: Advances in Management. American College of Surgeons Annual Meeting. October 12, 2008, Chicago, Illinois.

Moderator Bladder Cancer Podium Session. American Urological Association, Southeastern Section. March 9, 2008. San Diego, California.

Director, 7th Annual North Carolina Residents Seminar. September 18, 2007. Greensboro, North Carolina.

Moderator Bladder Cancer Podium Session. American Urological Association, Southeastern Section. March 9, 2007. Lake Buena Vista, Florida.

Director, 6th Annual North Carolina Residents Seminar. October 5, 2006. Greensboro, North Carolina.

Moderator Prostate Cancer Poster Session. American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico.

Director, 5th Annual North Carolina Residents Seminar. September 11, 2005. Greensboro, North Carolina.

Moderator Prostate Cancer Poster Session. American Urological Association, Southeastern Section. March 6, 2005. Charleston, South Carolina.

Director, 4th Annual North Carolina Residents Seminar. November 1, 2004. Greensboro, North Carolina.

Moderator – Laparoscopy Poster Session. American Urological Association, Southeastern Section. March 26, 2004. Aruba.

Director, 3rd Annual North Carolina Residents Seminar. October 3, 2003. Greensboro, North Carolina.

Director, 2nd Annual North Carolina Residents Seminar. September 15, 2002. Greensboro, North Carolina.

Course Director, Hand-Assisted and Laparoscopic Urology Course. Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire, June 10-11, 2002.

Director, 1st Annual North Carolina Residents Seminar. October 12, 2001. Greensboro, North Carolina.

Visiting Professorships

“Live Surgery – Robotic Cystectomy.” 6th Jiangsu Province Endourology Symposium, The 1st Affiliated Hospital of Nanjing Medical University, December 4, 2010, Nanjing, China.

“Robotic cystectomy.” Grand Rounds, 6th Jiangsu Province Endourology Symposium, The 1st Affiliated Hospital of Nanjing Medical University, December 3, 2010, Nanjing, China.

“Robotic radical cystectomy and bladder cancer.” University of Mississippi, March 3, 2010. University, Mississippi.

“Estrogen deficiency as a consequence of androgen deprivation therapy in men with prostate cancer.” University of Mississippi, March 3, 2010. University, Mississippi.

“Contemporary management of non-muscle-invasive bladder cancer” Advances in Urology 2009. Emory University, December 2, 2009. Atlanta, Georgia

“Robotic Radical Cystectomy” Advances in Urology 2009. Emory University, December 2, 2009. Atlanta, Georgia.

Robotic radical cystectomy for bladder cancer.” Harvard Programs in Urology, Harvard University, November 30, 2009, Boston, Massachusetts.

“Robotic radical cystectomy for bladder cancer.” Tulane University, November 15, 2009, New Orleans, Louisiana.

“Evaluation and Treatment Guidelines for Non-muscle invasive Bladder Cancer” Department of Urology Grand Rounds. Roswell Park Cancer Institute. September 4, 2008. Buffalo, New York.

“Current Concepts in the Treatment of Invasive bladder Cancer” Department of Urology Grand Rounds. Roswell Park Cancer Institute. September 4, 2008. Buffalo, New York.

“Robotic-assisted laparoscopic radical cystectomy: clinical and pathologic outcomes.” Vanderbilt University, Nashville, Tennessee. December 17, 2007.

“The role of COX-2 inhibitors in urologic oncology.” Visiting Professor, Department of Urology Grand Rounds. Stanford University. February 20, 2004. Stanford, California.

“The role of COX-2 inhibitors in oncology.” Department of Anesthesia, Pain Service Grand Rounds. Stanford University. February 20, 2004. Stanford, California.

Lectures

3rd Year Medical Students

September 28, 2009, Urologic Cancer

October 6, 2008, Urologic Cancer

August 11, 2008, Urologic Cancer

June 9, 2008, Urologic Cancer

July 23, 2007, Urologic Cancer

May 7, 2007, Urologic Cancer

February 5, 2007, Urologic Cancer

April 10, 2006, Genitourinary Complaints

September 27, 2005, Urologic Cancer
August 1, 2005, Urologic Cancer
February 14, 2005, Urologic Cancer
December 6, 2004, Urologic Cancer
September 27, 2004, Urologic Cancer
August 6, 2004, Urologic Cancer
June 2, 2004, Urologic Cancer
April 16, 2004, Urologic Cancer
February 10, 2004, Urologic Cancer
December 2, 2003, Urologic Cancer
October 7, 2003, Urologic Cancer
August 5, 2003, Urologic Cancer
May 30, 2003, Urologic Cancer
April 15, 2003, Urologic Cancer
December 2, 2002, Urologic Cancer
May 21, 2002, Urologic Cancer
April 12, 2002, Urologic Cancer
September 28, 2001, Urologic Cancer

2nd Year Medical Students

December 11, 2009, Urinary Course, Urologic Malignancies
December 11, 2008, Urinary Course, Urologic Malignancies
December 2007, Urinary Course, Urologic Malignancies
December 2006, Urinary Course, Urologic Malignancies
December 2005, Urinary Course, Genitourinary Tumors: Kidney, Bladder, Testis, External Male Genitourinary
December 10, 2004, Urinary Course, Genitourinary Tumors: Kidney, Bladder, Testis, External Male Genitourinary

Grand Rounds UNC

“Robotic Surgery for Bladder Cancer: Innovation, Investigation, and Widespread Application”
Department of Surgery Grand Rounds, University of North Carolina, April 7, 2010.

“Evaluating the Impact of Race in Prostate Cancer”, Department of Surgery Grand Rounds,
University of North Carolina, July 30, 2008.

"Current Concepts in the Treatment of Invasive Bladder Cancer" Department of Surgery Grand
Rounds, University of North Carolina. January 24, 2008.

“ Modern Concepts in the Treatment of Prostate Cancer.” Department of Surgery Grand Rounds,
University of North Carolina. January 14, 2005.

“The role of COX-2 inhibitors in urologic oncology.” Department of Surgery Grand Rounds,
University of North Carolina. January 14, 2004. Chapel Hill, North Carolina.

“Management of Invasive Bladder Cancer” Department of Surgery Grand Rounds, University of
North Carolina. August 6, 2002. Chapel Hill, North Carolina.

“PSA and Prostate Cancer”: Department of Medicine Grand Rounds, University of North
Carolina. May 6, 2002. Chapel Hill, North Carolina.

“PSA and Prostate Cancer”: Department of Family Medicine Grand Rounds, University of North Carolina. September 6, 2001. Chapel Hill, North Carolina

“Prostate Disease and Prostate Cancer” Westcare (UNC AHEC) Teleconference/Grandrounds. August 21, 2001. Chapel Hill North Carolina (teleconference).

“Surgical Treatment of Prostate Cancer: Indications, Techniques, and Outcomes”: Department of Surgery Grand Rounds, University of North Carolina. June 23, 2000, Chapel Hill, North Carolina.

Continuing Education Lecture

UNC

“Urologic Workforce: Past, Present & Future” 10th Annual Landes Symposium: Advances in Urology. UNC Urologic Surgery, Chapel Hill, North Carolina, June 22, 2012.

“Robotic radical cystectomy for treatment of bladder cancer” 8th Annual Landes Symposium: Advances in Urology. UNC Urologic Surgery, Chapel Hill, North Carolina, June 25, 2010.

“Radical cystectomy and urinary diversion.” Bladder Cancer Advocacy Network, North Carolina Patient Forum, Chapel Hill, North Carolina, May 15, 2010.

“The current role of prostate sparing cystectomy for bladder cancer” 7th Annual Landes Symposium: Advances in Urology. UNC Urologic Surgery, Chapel Hill, North Carolina, June 19, 2009.

“Evaluating the impact of race in prostate cancer” Medical Alumni Association Alumni Weekend. October 24, 2008. Chapel Hill, North Carolina.

“Modern Concepts in the Treatment of Prostate Cancer” Medical Alumni Association Alumni Weekend. October 24, 2008. Chapel Hill, North Carolina.

“Robotic Surgery on the Bladder” 2nd Annual International Gynecologic Oncology Symposium, October 17, 2008. Chapel Hill, North Carolina.

“Establishing a Robotic Surgical Program: Roundtable Discussion” 2nd Annual International Gynecologic Oncology Symposium, October 17, 2008. Chapel Hill, North Carolina.

“Guidelines in the treatment of non-invasive bladder cancer.” Sixth Annual Landes Symposium on the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 22, 2008. Chapel Hill, North Carolina.

“The robotic cystectomy program at UNC.” Sixth Annual Landes Symposium on the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 22, 2008. Chapel Hill, North Carolina.

“The multidisciplinary approach to urologic oncology.” Fifth Annual Landes Symposium on the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 15, 2007. Chapel Hill, North Carolina.

“The robotic cystectomy program at UNC.” Fifth Annual Landes Symposium on the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 15, 2007. Chapel Hill, North Carolina.

“Bone complications and their treatment in the prostate cancer patient” Fifth Annual Landes Symposium on the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 15, 2007. Chapel Hill, North Carolina.

“Understanding bone complications and their treatment in the prostate cancer patient.” Fourth Annual Landes Symposium on the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 23, 2006. Chapel Hill, North Carolina.

“Modern Approaches to the Treatment of Bladder Cancer.” Fourth Annual Landes Symposium on the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 23, 2006. Chapel Hill, North Carolina.

“Complex laparoscopic renal surgery.” Fourth Annual Landes Symposium on the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 23, 2006. Chapel Hill, North Carolina.

“Complex laparoscopic renal surgery.”. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 18, 2005. Chapel Hill, North Carolina.

“Understanding bone complications and their treatment in the prostate cancer patient.” Third Annual Landes Symposium on the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 17, 2005. Chapel Hill, North Carolina.

“COX-2 inhibitors in urology: current peril or future promise?” Third Annual Landes Symposium on the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 17, 2005. Chapel Hill, North Carolina.

“The multidisciplinary approach to urologic oncology.” Symposium on the Multidisciplinary Advances in the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. February 13, 2004. Chapel Hill, North Carolina.

“The role of COX-2 inhibitors in urologic oncology.” Symposium on the Multidisciplinary Advances in the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. February 13, 2004. Chapel Hill, North Carolina.

“Concepts and Controversies in the Management of Invasive Bladder Cancer” Symposium on the Multidisciplinary Advances in the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. February 13, 2004. Chapel Hill, North Carolina.

“Laparoscopic Renal Surgery” Symposium on the Multidisciplinary Advances in the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. February 13, 2004. Chapel Hill, North Carolina.

“The multidisciplinary approach to urologic oncology.” Advances in Oncology Nursing Symposium. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. November 12, 2003. Chapel Hill, North Carolina.

“Management of Rising PSA after definitive therapy for prostate cancer.” Symposium on the Multidisciplinary Advances in the Treatment of Prostate Cancer. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. February 1, 2003. Chapel Hill, North Carolina.

Outside UNC

Pruthi RS. Bladder/Kidney Cancer. Plenary Session, American Urological Association, May 23, 2012. Atlanta Georgia.

Round Table Panel: Establishing an Urology Oncology Program. 2011 Society of Urologic Oncology Winter Meeting. November 30, 2011. Bethesda, Maryland.

Discussion Panel, Dr. Douglas Sutherland: Proposal for a Surgical Technique RCT. 2011 Society of Urologic Oncology Winter Meeting. November 30, 2011. Bethesda, Maryland.

Pruthi RS. Take home messages for bladder cancer. Plenary Session, American Urological Association, June 3, 2010, San Francisco, California.

Pruthi RS. Bladder cancer take home points. Plenary Session, American Urological Association, June 2, 2010. San Francisco, California.

Pruthi RS. The role of robotic radical cystectomy for the management of invasive bladder cancer. Society of Urologic Oncology at the AUA, May 29, 2010, San Francisco, California.

Expansion of Robotics in Urologic Oncology: Video of technique and summary of outcomes. 5th International Congress, Minimally Invasive Robotics Association, January 27, 2010. San Diego, California.

Extracorporeal and intracorporeal urinary diversion after robotic cystectomy. International Robotic Urology Symposium, January 16, 2010. Las Vegas, Nevada.

Androgen Deprivation Therapy Induced Estrogen Deficiency Side Effects. Birmingham Urology Society, Birmingham, Alabama. December 9, 2009.

Androgen Deprivation Therapy Induced Estrogen Deficiency Side Effects. Tulane University, New Orleans, Louisiana. December 8, 2009

Management of recurrent superficial bladder cancer. Emory University, Advances in Urology 2009, December 4, 2009. Atlanta, Georgia.

Robotic-assisted cystectomy. Emory University, Advances in Urology 2009, December 4, 2009. Atlanta, Georgia.

Androgen Deprivation Therapy Induced Estrogen Deficiency Side Effects, Beth Israel/Brigham and Women’s Program. December 2, 2009.

Current Concepts in the Management of Non-Invasive Bladder Cancer, Wilmington Urology Association, Wilmington, North Carolina. December 1, 2009.

Current Concepts in the Management of Non-Invasive Bladder Cancer, Eastern North Carolina Urology Association. November 3, 2009.

Androgen Deprivation Therapy Induced Estrogen Deficiency Side Effects, New England Section of the AUA, Washington, DC. September 25, 2009.

“Novel Treatments for Localized Prostate Cancer – Cryo and HIFU” IAUA meeting at the AUA. April 25, 2009, Chicago, Illinois.

“Clinical Care Pathways in Urologic Surgery” Surgical Techniques in Urologic Oncology. AUA Course. March 21, 2009, Las Vegas, Nevada.

“Principles and Technical Considerations for Partial Nephrectomy” Surgical Techniques in Urologic Oncology. AUA Course. March 21, 2009, Las Vegas, Nevada.

“Robotic Pelvic Lymphadenectomy for Prostate and Bladder Cancer” Surgical Techniques in Urologic Oncology. AUA Course. March 21, 2009, Las Vegas, Nevada.

“Prostate-sparing Radical Cystectomy” Surgical Techniques in Urologic Oncology. AUA Course. March 21, 2009, Las Vegas, Nevada.

Technical Aspects for Transrectal Ultrasound-guided Prostate Biopsy” Surgical Techniques in Urologic Oncology. AUA Course. March 20, 2009, Las Vegas, Nevada.

“Robotic cystectomy” Roundtable discussion. Society of Urologic Oncology. December 4, 2008. Bethesda, Maryland.

“Robotic cystectomy and pelvic lymphadenectomy” Plenary session. World Congress of Endourology. December 2, 2008. Shanghai, China.

“New surgical technology in the treatment of prostate cancer: robotics, cryotherapy, and HIFU” Management of Localized Prostate Cancer Course, American College of Surgeons, October 14, 2008. San Francisco, California.

“Modern Concepts in the Treatment of Invasive Bladder Cancer” ACS Course: Carcinoma of the Bladder: Advances in Management. American College of Surgeons Annual Meeting, October 12, 2008, Chicago, Illinois.

“Evaluating the impact of race in prostate cancer” Department of Surgery Grand Rounds, University of North Carolina. July 24, 2008.

“Robotic-assisted laparoscopic radical cystectomy: technique and early experience.” Intuitive Corporation Seminar at AUA. Orlando, Florida, May 19, 2008.

“Professional Pathways Career Choices” Young Urologists Forum. Southeast Section of the American Urological Association. March 8, 2008. San Diego, California.

Treatment of high-risk cancer.” Jacksonville, Florida, November 4, 2007.

“Robotic-assisted laparoscopic radical cystectomy: clinical and pathologic outcomes.” Urologic Research Society, California, October 26, 2007.

“Debate on the management of small renal masses: Observation” Northeastern Section of the American Urological Association. September 9, 2007. Rochester, New York.

“Management of Invasive Bladder Cancer” Centennial Congress of the Societe Internationale d’Urologie (SIU). September 4, 2007. Paris, France.

“Health disparities in prostate cancer” Texas Health Disparities Conference. May 31, 2007. Fort Worth, Texas.

“Bone complications and their treatment in the prostate cancer patient.” Alamance Regional Cancer Center. April 30, 2007. Burlington, North Carolina.

“Emerging Concepts in the Multidisciplinary treatment of high risk prostate cancer.” Kugelman Cancer Center Urology-Oncology Rounds. April 30, 2007. Pensacola, Florida.

“Managing skeletal complications in the prostate cancer patient.” Rowan County Oncology Rounds. April 17, 2007. Salisbury, North Carolina.

“Bone complications and their treatment in the prostate cancer patient.” Rex Cancer Center Rounds. April 11, 2007. Raleigh, North Carolina.

“Emerging Concepts in the Treatment of Invasive Bladder Cancer.” First Annual Urology Congress. April 6, 2007. San Francisco, California.

“Management of High-risk Patients with Prostate Cancer”. Duke-UNC Urologic Oncology Forum. March 29, 2007. Durham, North Carolina.

“Emerging Concepts in the Treatment of Bladder Cancer including the Potential of Robotic Cystectomy” Department of Urology Grand Rounds. Wake Medical Center. February 21, 2007. Raleigh, North Carolina.

“Bone complications and their treatment in the prostate cancer patient.” Western Carolina Oncology Society. December 1, 2006. Asheville, North Carolina.

“Modern Concepts in the Treatment of Bladder Cancer including the Potential of Robotic Cystectomy” Department of Urology Grand Rounds. Duke University. October 22, 2006. Durham, North Carolina.

“Promise and potential of COX-2 inhibitors in Urology.” Visiting Professor, Department of Urology Grand Rounds. Medical College of Georgia. June 22, 2006. Augusta, Georgia.

“Modern Approaches to the Treatment of Prostate Cancer.” Oncology Grand Rounds, Spartanburg Regional Medical Center. May 3, 2006, Spartanburg, North Carolina.

“Prostate Cancer Clinical Trials and the Evolving Area of Prostate Cancer Therapy.” Oncology Rounds, New Hanover Regional Medical Center. March 21, 2006, Wilmington, North Carolina.

“Prostate Cancer Clinical Trials at The University of North Carolina at Chapel Hill.” Duke Prostate Cancer Symposium. April 9, 2005, Durham, North Carolina.

“Modern approaches to the Treatment of Prostate Cancer.” Legends Annual Meeting. The University of North Carolina at Chapel Hill. April 3, 2005, Chapel Hill, North Carolina.

“Robotics, laparoscopy, and other novel surgical approaches to the treatment of prostate cancer.” Annual Oncology Nursing Forum at the University of North Carolina. The University of North Carolina at Chapel Hill. March 15, 2005, Chapel Hill, North Carolina.

“The role of COX-2 inhibitors in urologic oncology.” Urologic Oncology Research Disease Group Rounds, Department of Urology. University of Iowa. November 19, 2004. Iowa City, Iowa.

“Promise and potential of COX-2 inhibitors in urology.” Visiting Professor, Department of Urology. University of Iowa. November 18, 2004. Iowa City, Iowa.

“The role of COX-2 inhibitors in urologic oncology.” Piedmont Urological Society. August 9, 2004. Winston-Salem, North Carolina.

“The role of COX-2 inhibitors in urologic oncology.” Eastern Shore Medical Society. April 21, 2004. Baltimore, Maryland.

“The role of COX-2 inhibitors in urologic oncology.” Department of Urology Grand Rounds. Hopkins-Bayview Medical Center. April 20, 2004. Baltimore, Maryland.

“The role of COX-2 inhibitors in urologic oncology.” Department of Urology Grand Rounds. University of Maryland. April 19, 2004. Baltimore, Maryland.

“Urology Review”: American Academy of Physicians Assistants Annual Review Course. February 24, 2004.

“Modern concepts in the treatment of prostate cancer.” Oncology Grand Rounds. Watauga Memorial Hospital. October 17, 2003.

“Modern concepts in the treatment of prostate cancer.” Medical Grand Rounds. Gastonia Memorial Hospital. August 17, 2003.

“The role of COX-2 inhibitors in urologic oncology.” Making a Difference in Oncology. Sponsored by Moffitt Cancer Center, The University of South Florida. April 26, 2003. Phoenix, Arizona.

“The Role of Laparoscopy in Urologic Oncology”: Tri-County Urology Meeting. Fayetteville, North Carolina. March 11, 2003.

“The role of COX-2 inhibitors in urologic oncology.” Oncology Grand Rounds. The University of Maryland. March 6, 2003. Baltimore, Maryland.

“The role of COX-2 inhibitors in urologic oncology.” Eastern Shore Medical Society. March 6, 2003. Baltimore, Maryland.

“The role of COX-2 inhibitors in urologic oncology.” Grand Rounds. Saint Josephs Hospital. March 5, 2003. Baltimore, Maryland.

“Concepts and Controversies in the Management of Invasive Bladder Cancer”: Eastern Carolina Urological Association. September 17, 2002. Greenville, North Carolina.

“Laparoscopic Nephrectomy, Partial Nephrectomy and Renal Cyst Marsupialization: Surgical Technique”: Invited Lecturer, Carolinas Laparoscopy & Advanced Surgery Program. September 6, 2002. Charlotte, North Carolina.

“Current Controversies in the Management of Invasive Bladder Cancer”: Carolina Urological Association 72nd Annual Meeting. August 30-September 1, 2002. Wrightsville Beach, North Carolina.

“Laparoscopic Nephrectomy and Renal Cyst Marsupialization: Surgical Technique”: Urology Grand Rounds. June 29, 2002. Wilmington, North Carolina.

“Laparoscopic Nephrectomy: History and Contemporary Applications”: Urology Grand Rounds. Dartmouth-Hitchcock Medical Center. June 11, 2002. Hanover, New Hampshire.

“Current Concepts in Urinary Diversion”: Society of University Urological Residents 37th Annual Meeting. May 23-24, 2002. Orlando, Florida.

“The Role of Laparoscopy in Urologic Oncology”: Wake County Urology Meeting. May 15, 2002. Raleigh, North Carolina.

“Urology Review”: American Academy of Physicians Assistants Annual Review Course. February 24, 2002.

“PSA and Prostate Cancer”: Randolph County Medical Association. January 22, 2001. Asheboro, North Carolina.

“Surgical Treatment of Renal Cell Carcinoma: Past, Present, and Future”: National Kidney Cancer Association. October 14, 2000. Research Triangle Park, North Carolina.

“The Role of Laparoscopy in Urologic Oncology”: Triad Urological Society. August 9, 2000. Winston-Salem, North Carolina.

“Prostate Cancer Update”: Pender County Medical Association. April 3, 2000. Burgaw, North Carolina.

“PSA doubling times in patients who fail radical prostatectomy: correlation with histology of the primary cancer”: Department of Urology Grand Rounds, Louisiana State University. March 30, 1999. Shreveport, Louisiana.

“PSA doubling times and times to PSA recurrence in patients who fail radical prostatectomy”: Division of Urology Grand Rounds, Dartmouth-Hitchcock Medical Center. February 27, 1999. Hanover, New Hampshire.

Clinical Teaching

Clinical Teaching - urology residents. UNC School of Medicine. 4/00 - present

Clinical Teaching - urology residents. LSU School of Medicine, 7/99 – 4/00

Preceptor for Student/Resident Research Projects

Residents

Stephen McKim, MD – Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A Phase II trial. (2009 – 2010)

Stephen McKim, MD – A neoadjuvant clinical trial with sorafenib for patients with Stage II or greater renal cell carcinoma. (2009 – 2010)

Eugene Simopoulos, MD – Elimination of bowel preparation in patients undergoing cystectomy and urinary diversion. (2009 – 2010)

Angela Smith, MD – Multi-institutional analysis of robotic radical cystectomy for bladder cancer: perioperative outcomes in 227 patients. (2009 – 2010)

Eugene Simopoulos, MD – Fast track program in patients undergoing radical cystectomy: experience in 362 consecutive cases. (2009 – 2010)

Angela Smith, MD – Robotic-assisted laparoscopic radical cystectomy: evaluation of the learning curve. (2009 – 2010)

R Matt Coward, MD – Cost analysis of robotic-assisted laparoscopic radical cystectomy for bladder cancer. (2009 – 2010)

R Matt Coward, MD – A Phase II study of neoadjuvant erlotinib (Tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy: preliminary results. (2009 – 2010)

J Slade Hubbard, MD – Robotic anterior pelvic exenteration for bladder cancer in the female: outcomes and comparisons to their male counterparts. (2008 – 2009)

Kelly Swords, MD – The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme. (2008 – 2009)

Aaron Lentz, MD – Impact of marital status in patients undergoing radical cystectomy for bladder cancer. (2008 – 2009)

Kelly Swords, MD – The impact of race on prostate cancer detection and choice of treatment in men undergoing a contemporary extended biopsy approach. (2008 – 2009)

Angela Smith, MD – Evaluating the learning curve for robotic-assisted laparoscopic radical cystectomy. (2008 – 2009)

Matt Pearson, MD - Robotic-assisted laparoscopic radical cystectomy. (2007 - 2008)

Jeff Nix, MD - Relationship of obesity and incidental prostate cancer detection in men undergoing radical cystoprostatectomy for bladder cancer. (2007 - 2008)

Matt Pearson, MD - A Phase II study of neoadjuvant erlotinib (Tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy. (2007 - 2008)

Jeff Nix, MD - Partial cystectomy for bladder cancer: analysis of recent trends in its use and misuse. (2007 - 2008)

Jeff Nix, MD - Robotic-assisted laparoscopic radical cystectomy: evaluation of the learning curve. (2007 - 2008)

Matt Pearson, MD - Robotic-assisted laparoscopic versus open radical cystectomy: comparisons of a simultaneous experience. (2007 - 2008)

Jeff Nix, MD - The impact of bladder neck sparing modification on surgical and functional outcomes after robotic-assisted laparoscopic radical prostatectomy? (2007 - 2008)

Matt Pearson, MD - Effect of neoadjuvant tyrosine kinase inhibitors on patients undergoing radical nephrectomy. (2007 - 2008)

Jeff Nix, MD - Impact of obesity on operative, pathologic, and functional outcomes after robotic-assisted laparoscopic radical prostatectomy. (2007 - 2008)

Matt Pearson, MD - The impact of bladder neck sparing modification on surgical and functional outcomes after robotic-assisted laparoscopic radical prostatectomy. (2006 - 2008)

Vishal Bhalani, MD - Expectant management of patients with low-risk superficial bladder cancer. (2007 - 2008)

Javier Miller, MD - Prospective evaluation of short-term impact and recovery of health related quality of life (HRQOL) in ment undergoing robotic-assisted laparoscopic radical prostatectomy vs open radical prostatectomy (ORP). (2005 - 2007)

Aaron Lentz, MD - A comparison of the Bricker versus Wallace ureteroileal anastomosis in patients undergoing urinary diversion for bladder cancer. (2005 - 2007)

Aaron Lentz, MD - Stomal complications in patients undergoing radical cystectomy and ileal conduit urinary diversion for bladder cancer. (2005 - 2007)

Javier Miller, MD - Accuracy of MR and CT cross sectional imaging in the staging of invasive bladder cancer: a prospective study blinded to clinical outcome. (2005 - 2007)

Aaron Lentz, MD - Robotic-assisted laparoscopic radical cystectomy: initial experience and operative outcomes. (2005-2006)

Adam Hickerson, MD - The impact of race and gender in patients undergoing radical cystectomy for bladder cancer. (2006 - 2007)

Daniel McRackan, MD - Expectant management of small renal masses: does a delay in therapy pose a clinical or pathological risk to the patient. (2006 - 007)

Joseph Moliterno, MD - Incidental finding of prostate cancer at cystoprostatectomy: changes in incidence in the PSA era. (2004 - 2006)

Adam Hickerson , MD - Laparoscopic retroperitoneal lymph node dissection for low-stage testicular cancer: challenges and benefits. (2004 - 2006)

Daniel McRackan, MD - Recent experience of surgical management of renal masses: the evolution of laparoscopic approaches in clinical practice. (2004 - 2006)

Adam Hickerson, MD - Evaluation of the routine use of metocloperamide in patients undergoing radical cystectomy and urinary diversion. (2004 - 2006)

Daniel McRackan, MD - An evaluation of prostate cancer knowledge in patients with prostate cancer and their partners. (2004 - 2006)

Daniel McRackan, MD - An evaluation of prostate cancer knowledge in patients with prostate cancer: impact of demographic and socioeconomic variables. (2004 - 2006)

Adam Hickerson, MD - Impact of race on treatment selection and disease progression in men who choose observation for clinically-localized prostate cancer. (2004 - 2006)

Adam Hickerson, MD - Watchful waiting for patients with locally-advanced and node-positive prostate cancer: biochemical and clinical outcomes. (2004 - 2006)

J Slade Hubbard, MD - Hand assisted laparoscopic nephrectomy for large renal masses. (2003 - 2005)

Heather Stefaniak, MD - Neoadjuvant docetaxel and estramustine followed by radical prostatectomy or radiation therapy for patients with high-risk prostate cancer. (2003 - 2005)

J Slade Hubbard, MD - Prospective evaluation of short-term impact and recovery of health-related quality of life (HRQOL) in men undergoing radical prostatectomy (RP). (2003 - 2005)

J Eric Derksen, MD - Efficacy and safety of en bloc ligation of the renal hilum at the time of laparoscopic nephrectomy: review of 62 consecutive cases. (2003 - 2005)

J Eric Derksen, MD - Phase II trial of celecoxib in PSA recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. (2003 - 2005)

Joseph Moliterno, MD - Incidental finding of prostate cancer at cystoprostatectomy: changes in incidence in the PSA era. (2002 - 2004)

J Eric Derksen, MD - Safe and effective application of laparoscopic partial nephrectomy for small renal masses: duplication of open principles and practices. (2002 - 2004)

J Eric Derksen, MD - Hand assisted laparoscopic nephrectomy for large renal masses. (2002 - 2005)

Aubrey Evans, MD - Complications and reasons for prolonged stay in patients undergoing radical cystectomy utilizing a perioperative pathway. (2002 - 2005)

Aubrey Evans, MD - Costs and surgical outcomes associated with radical cystectomy: changes over the past decade. (2002 - 2005)

Heather Stefaniak, MD - The use of the COX-2 inhibitor celecoxib to reduce perioperative pain associated with radical retropubic prostatectomy (RRP). (2002 - 2005)

Sean McLaughlin, MD - Potential role of initial incision of the lateral pelvic fascia, development of a perirectal pocket, and early ligation of the vascular pedicles in reducing positive margins during radical prostatectomy. (2002 - 2004)

Chris Tornehl, MD - Initial experience with fibrin tissue sealants during laparoscopic partial nephrectomy. (2002 - 2004)

John Kang, MD - Comparison of grade and stage in African American and Caucasian patients with prostate cancer: evaluation of clinical, biopsy, and surgical pathology. (2002 - 2004)

Kris Gaston, MD - Impact of race, age, income, and residence on prostate cancer: evaluation of clinical, biopsy, and surgical pathology. (2002 - 2004)

Chris Tornehl, MD - Partial nephrectomy with fibrin glue repair: measurement of vascular and pelviciceal bond integrity in a live porcine animal model. (2002 - 2004)

Sean McLaughlin, MD - Expression of cyclooxygenase-2 in human renal cell carcinoma. (2002 - 2004)

Sean McLaughlin, MD - Comparison of clinical and pathological staging in patients undergoing primary versus delayed radical cystectomy for bladder cancer. (2002 - 2004)

Sean McLaughlin, MD - Potential role of initial incision of the lateral pelvic fascia, development of a perirectal pocket, and early ligation of the vascular pedicles in reducing positive margins during radical prostatectomy. (2002 - 2004)

Sean McLaughlin, MD - Reducing time to oral diet and hospital discharge in patients undergoing radical cystectomy. (2002 - 2004)

Kris Gaston, MD - Impact of race, age, income, and residence on prostate cancer (CaP) knowledge, screening behavior, and health maintenance in siblings of patients with CaP. (2001 - 2003)

Kris Gaston, MD - Impact of a sibling's diagnosis of prostate cancer (CaP) on prostate cancer knowledge, screening behavior and other health-related activities. (2001 - 2003)

J Eric Derksen, MD - The use of the COX-2 inhibitor celecoxib in PSA-recurrent prostate cancer (CaP) after radiation therapy or radical prostatectomy: 12 month follow-up. (2001 - 2003)

J Eric Derksen, MD - Early urethral catheter removal after radical retropubic prostatectomy. (2001 - 2003)

Joseph Moliterno, MD - Incidental finding of prostate cancer at cystoprostatectomy. (2001 - 2003)

J Eric Derksen, MD - Factors affecting length of stay after radical retropubic prostatectomy. (2001 - 2003)

Judy Chun, MD - The use of fibrin tissue sealants during laparoscopic partial nephrectomy. (2001 - 2003)

Joseph Moliterno, MD - Characterization of PSA doubling time in patients who have failed radical prostatectomy. (2001 - 2003)

Kris Gaston, MD - The use of erythropoietin in patients undergoing prostatectomy: effects of hematocrit, transfusion rates, and quality of life. (2000 - 2002)

J Eric Derksen, MD - COX-2 inhibitors in PSA-recurrent prostate cancer: a pilot study. (2000 - 2002)

Kris Gaston, MD - Hand-assisted laparoscopic nephrectomy: prospective evaluation of the learning curve. (2000 - 2002)

John Kang, MD - Impact of positive biopsy location on final tumor extent and unfavorable pathological outcomes in prostate cancer. (1999 - 2001)

John Kang, MD - Comparison of grade and stage in African American and Caucasian patients with prostate cancer: evaluation of clinical, biopsy, and surgical pathology. (1999 - 2001)

John Kang, MD - Impact of positive apical biopsies on unfavorable pathological outcomes in prostate cancer. (1999 - 2001)

John Kang, MD - Unilaterally-positive sextant biopsies useful for predicting final pathology. (1999 - 2001)

Students

Benjamin Waldorf – Long-term follow up of patients initially managed with active surveillance for solid renal masses. (2009 – 2010)

Elizabeth Dray – Use and outcomes of adjuvant chemotherapy in PT3-4 or node positive bladder cancer: analysis of a modern surgical cohort. (2009 – 2010)

Raj Kurpad – Robotic-assisted laparoscopic pelvic lymphadenectomy. (2009 – 2010)

Matthew Sand – Impact of marital status in patients undergoing radical cystectomy for bladder cancer. (2009 – 2010)

Ashley Brandon – Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. (2008 – 2009)

Jim Belsante – Robotic cystectomy and the internet: separating fact from fiction. (2008 – 2009)

Raj Kurpad – A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions? (2008 – 2009)

Erik Kouba - Characterization of pT3A renal carcinoma in tumors less than 4.0 cm in size. (2006 - 2008)

Stephen McKim - Trends of length of stay in patients undergoing radical cystectomy. (2007 - 2008)

Stephen McKim - Trends of cystectomy use in octogenarians with bladder cancer. (2007 - 2008)

Erik Kouba - Clinical usefulness of serum Ca 125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. (2006 - 2008)

Kelly Swords - Diagnostic rates and other outcomes based on initial versus repeat biopsy in a cohort of men undergoing a modern biopsy (10-12 cored) scheme. (2006 - 2007)

Angela Smith - Impact of surgical treatment of renal carcinoma on renal function and blood pressure: a race- and age-dependent association. (2006-2007)

Angela Smith - Gender-dependent associations between body composition in patients with renal cell carcinoma (RCC). (2006 - 2007)

Erik Kouba - Impact of marital status in patients undergoing radical cystectomy for bladder cancer. (2006 - 2007)

Eric Kouba - Characterization of acute phase inflammation in men undergoing robotic-assisted laparoscopic radical prostatectomy (RALRP). (2006 - 2007)

Kelly Swords - Diagnostic rates and other outcomes based on initial versus repeat biopsy in a modern cohort of men undergoing an extended biopsy (10-12 core) scheme. (2006 - 2007)

James Thomasch - Impact of race on time to androgen independence and subsequent biochemical progression in men with advanced prostate cancer. (2004 - 2006)

N Hawke - Phosphorylated serine 536 as an indicator of NF (B activity in prostate Cancer). (2003 - 2004)

Erik Kouba - Partial nephrectomy with fibrin glue repair: measurement of vascular and pelviciceal bond integrity n a live porcine animal model. (2003 - 2004)

Attending on Clinical Service

Attending - urology clinical service. UNC School of Medicine, 4/00 - present

Attending - urology clinical service. LSU School of Medicine, 7/99 - 4/00

Grants

Active

1. Not Assigned (Pruthi) 1/7/10 – 1/6/13 % of Effort: 5.00%
Adolor Corporation \$12,240.00

14CL403 A Phase 4, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study of Alvimopan for the Management of Postoperative Ileus in Subjects Undergoing Radical Cystectomy.

The primary objective of this study is to determine that alvimopan accelerates recovery of gastrointestinal (GI) function in subjects undergoing radical cystectomy.

Pending

1. Not Assigned (Davis) 9/30/11 – 9/29/14 % of Effort: 0.00%
US Department of Defense \$134,068.00

Classifying Human Kidney Cancers by Comprehensive Analysis of Chromatin Organization.

We have developed a new method to examine the structure of DNA in tumor cells. This test can identify important differences between tumors that look identical under the microscope. These differences have direct implications for the treatment of the cancer. We propose applying this method to study kidney cancer.

2. Not assigned (Pruthi) 7/1/11 – 6/30/16 % of Effort: 2.00%
University of Texas at San Antonio \$25,000.00

Robot Assisted Versus Open Radical Cystectomy: A Randomized Clinical Trial.

To evaluate and compare long term measures of recovery outcomes and functional independence between RARC and ORC.

3. Not Assigned (Nielsen) 7/1/11 – 6/30/13 % of Effort: 5.00%
National Institutes of Health \$54,212.00

Complexities of Decision Making in Older Adults with Low Risk Bladder Cancer.

This proposal aims to explore patient knowledge and information needs in this setting and preferences regarding invasive surveillance practices contextualized as such.

4. Not Assigned 4/1/11 – 3/31/16 % of Effort: 0.00%
National Institutes of Health \$602,711.00

Dissecting Complex Signatures from Renal Cell Carcinoma.

This proposal describes a broad based collaboration between experts in fields of biomarker development using transcriptional, non-coding RNA, and chromatin analysis for the establishment of a comprehensive set of multianalyte biomarkers for renal cell carcinoma that can be assessed with a single clinical tool.

5. Not Assigned 1/1/11 – 12/31/13 % of Effort: 0.00%
Lineberger Comprehensive Cancer Center \$499,000.00

LCCC 1028: Neoadjuvant Pazopanib: A Phase II Study to Evaluate the Effect on Disease Response and Recurrence and to Establish Biomarkers of Drug Activity in Renal Cell Carcinoma.

6. Not Assigned (Satia) 12/1/09-11/30/11 % of Effort: 4.00%
National Inst. of Health \$125,000.00

Effect of supplemental omega-3 fatty acids in patients with superficial bladder cancer after transurethral resection: a randomized trial

The primary specific aim is to evaluate whether dietary supplementation of two doses of omega-3 fatty acids (1800 mg and 3600 mg daily) for 9 months can reduce one-year (post initiation of the intervention) recurrence rates in patients with low-risk, superficial bladder cancer after transurethral endoscopic resection. OVERLAP NONE (Note: Submitted but delayed due to death of Principal Investigator)

Completed

Co Investigator; Satia J, Principal Investigator. Supplemental Omega-3 Fatty Acids, Serum PSA, and Inflammation in Men with Prostate Cancer. NIH. 12/1/08 – 11/30/10.

Co-Investigator; Satia J, Principal Investigator. Inflammation, Oxidative DNA Damage, and Nutrient Biomarkers in Prostate Cancer Patients. NIH. 12/1/08 – 11/30/10.

Prostate Cancer: Transition To Androgen-Independence: Core B. National Cancer Institute. 4/1/05 – 6/30/10.

Phase III Trial of Selenium for Prostate Cancer - Subcontract with the University of Arizona. National Cancer Institute. 11/1/98 – 4/30/10.

Co-Principal Investigator; Smith M, Principal Investigator. A randomized Double Blind Placebo-Controlled Phase III Study of Early vs Standard Zolodronic Acid to Prevent Skeletal Related Events in Men with PCa –Metastatic to Bone. CALGB. 3/05 – 12/09.

Co-Investigator; Rathmell W.K., Principal Investigator. Phase II trial of Novel Vaccine in Patients with Metastatic Renal Cell Carcinoma. Merix Inc. 6/04 – 12/09.

Co-Investigator; Rathmell W.K., Principal Investigator. Phase II trial of BAY-046 in Patients with Metastatic Renal Cell Carcinoma. Bayer Inc. 10/04 – 12/09.

A Multi-Center, Randomized, Double Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients with Bladder Cancer Undergoing Radical or Total Cystectomy. Kendle International Inc. 9/28/06 – 9/27/09.

Principal Investigator. A Phase II Trial of Plenaxis as Intermittent Therapy in Advanced Prostate Cancer. Lineberger Comprehensive Cancer Center / Praecis Inc. 3/05 – 6/09.

Co-Investigator. Rathmell W.K., Principal Investigator. A Phase II Trial of neoadjuvant sorafanib in patients with high risk renal cell carcinoma undergoing radical nephrectomy. Lineberger Comprehensive Cancer Center / Bayer / Onyx Inc. 11/06 – 12/09.

Co-investigator; Wallen EM., Principal Investigator GST-Pi – 002 Quantitative GST-Pi Methylation BX tissue testing to Improve the Accuracy of Ca Detection in Men with High Risk Localized PCa Lineberger Comprehensive Cancer Center / Oncomethylone. 2/05 – 12/09.

Co-Investigator. Meshel M., Principal Investigator. Decision-making and Uncertainty in Men Diagnosed with Prostate Cancer. National Institutes of Health. 6/03 – 12/09.

Co-investigator; Whang Y., Principal Investigator. A phase II study of Oral Once daily GW572016 (Lapatinib) in pts. With Hormone Refractory PCa (LCCC0505). Lineberger Comprehensive Cancer Center / GlaxoSmithKline. 3/05 – 12/08.

Co-Investigator. Mohler JM., Principal Investigator. Understanding Racial Differences in Prostate Cancer. U.S. Department of Defense Prostate Cancer Research Program Consortium (3-year, \$9.9M) 8/1/04 – 12/07.

Principal Investigator. Partial nephrectomy with fibrin glue repair: measurement of vascular and pelvic/cecal bond integrity in a live porcine and isolated abattoir animal model utilizing Tisseel fibrin tissue sealant. Baxter, Inc. 6/03 – 1/04.

Co-Principal Investigator; Droller M., Principal Investigator. An open comparative within-patient controlled phase III multicenter study of Hexvix fluorescence cystoscopy and standard cystoscopy in the detection of carcinoma-in-situ in patients with bladder cancer. Photocure Inc. 8/15/00 – 1/1/04.

Co-investigator; Whang Y., Principal Investigator. A phase II trial of Atrasentin in men with metastatic, hormone-refractory prostate cancer. Abbott Laboratories. 6/02 – 6/03.

Co-investigator. A phase II randomized-discontinuation study of oral CEP-701 in prostate cancer patients who have failed first-line hormonal therapy. TAP Holdings, Inc. 11/1/00 – 6/1/03.

Co- Investigator; Ornstein DK, Principal Investigator. SELDI analysis of serum proteins: a novel approach to improve early prostate cancer detection. Lineberger Comprehensive Cancer Center, UNC. 10/15/00 – 8/1/03.

Co-Principal Investigator; Lewis J, Principal Investigator. A multi-center randomized phase III study of adjuvant Oncophage(versus observation in patients with high risk of recurrence after surgical treatment for renal cell carcinoma. Antigenics Inc. 5/15/00 – 8/1/03.

Co-Principal Investigator; Cote RJ, Principal Investigator. MVAC in organ-confined bladder cancer based on p53 status. National Cancer Institute. 11/1/97 – 12/00.

Co-investigator; Schroeder J, Principal Investigator. Estimation of risks of development of renal cell carcinoma: evaluation of the effect of genetic polymorphisms in conjunction with environmental factors. National Institutes of Health. (submitted 10/04)

Professional Service

Discipline

Chair of the Surgical Forum for Urology, American College of Surgeons, 1/12-present.

Member American College of Surgeons, Committee on Video-based Education, 10/2011-10/2014

ABU/AUA Examination Committee Member, 08/2011-07/2014

Editorial Board, Archivos Espanoles De Urologia, 11/10 - present

Charter Member, Society of Robotic Surgery, 9/10 - present

Editorial Board, *The Annals of Urology*, 9/10 - present

Reviewer, *Tumor Biology*, 9/10 - present

Member, Bladder Cancer Guidelines Committee, International Consultation on Urological Diseases, 5/10 – present.

Vice Chair, Scientific Committee, Indian American Urological Association, 5/10 - present

Editorial Board, *World Journal of Clinical Oncology*, 1/10 - present

Vice Chair, Young Urologists Committee, American Urological Association, 5/09 – 5/10.

Editorial Board, *Journal of Urology*, 4/09 – present

Member, American College of Surgeons Advisory Council for Urology, 10/08 – present

Member, Planning Committee, Indian American Urological Association Meeting, 10/08 - present

Editorial Board, *The Open Surgical Oncology Journal*, 10/08 – present

Editorial Board, *Open Access Journal of Urology*, 10/08 – present

Editorial Board, *Case Reports in Medicine*, 7/08 – present

Member, Board of Directors (NC alternate representatives), Southeastern Section of the American Urological Association, 5/08 – present

Editorial Board, *World Journal of Urology*, 11/07 – present

Consultant *Journal of Women's Health*, 9/07 – present

Consultant *Expert Review of Anticancer Therapy*, 9/07 – present

Member, Young Urologists Committee, American Urological Association, 6/07 - present

Member, American College of Surgeons Committee on Young Surgeons, 5/07 - present

Member, Young Urologists Leadership Committee, Southeastern Section of the American Urological Association, 3/07 - present

Consultant *Issues in Urology*, 3/07 – present

Consultant *Lancet Oncology*, 3/07 – present

Consultant *Expert Opinion on Pharmacotherapy*, 3/07 – present

Consultant *International Brazilian Journal of Urology*, 3/07 – present

Consultant *Indian Journal of Urology*, 2/07 – present

Consultant *TSW Urology*, 11/06 – present

Consultant *Cancer*, 3/06 – present

Consultant *Archives of Medical Research*, 3/06 – present

Consultant *Journal of Endourology*, 1/06 – present

Invited Member, Urological Research Society, 11/05 – present

Surgical Principal Investigator, University of North Carolina -- Cancer and Leukemia Group B (CALGB), 7/05 - present

Consultant, *European Urology*, 6/05 – present

Editorial Board, *Prostate Cancer and Prostatic Diseases*, 3/05 – present

Consultant, *British Journal of Urology*, 1/05 – present

Consultant, *Apoptosis*, 10/04 – present

Panel Member, Bladder Cancer Clinical Guidelines, *American Urological Association*, 6/04 - present

Consultant, *Urology*, 6/03 – present

Consultant, *Urologic Oncology*, 1/03 - present

American College of Surgeons, 2003-present

Consultant, *Journal of Urology*, 1/02 – present

Editorial Advisory Board, *Contemporary Urology*, 1/02 – present

Society of Urologic Oncology, 2002 – present

Core Member, Genitourinary Committee – Cancer and Leukemia Group B (CALGB), 10/00 - present

Triangle Urological Society, 2000 – present

American College of Surgeons Oncology Group, 2000 – present

Cancer and Leukemia Group B – genitourinary core member, 2000 – present

Southeast Section - American Urological Association, 1998 – present

American Urological Association, 1996 – present

Within UNC

Co-Director of Urologic Oncology Group, Lineberger Comprehensive Cancer Center- UNC School of Medicine, 11/11- present.

Faculty Leadership Initiative – UNC – 9/10 – 11/10

Urology Service Leader – UNC – 6/09 - present

Member, Regional Strategies Working Group - North Carolina Cancer Hospital - UNC School of Medicine, 1/07 – present.

Disease Group Leader, Urologic Oncology, Lineberger Comprehensive Cancer Center - UNC School of Medicine, 1/03 – 1/07

Member, Executive Committee - North Carolina Cancer Hospital - UNC School of Medicine, 11/06 – present.

Head, Section of Urologic Oncology; Division of Urologic Surgery - UNC School of Medicine, 2/03 – present

Director of Ambulatory Care, Department of Surgery UNC School of Medicine, 11/02 – present

Member, Compensation Task Force, Department of Surgery - UNC School of Medicine, 7/02 – present

Member, Surgery Quality Assurance Committee, UNC School of Medicine, 1/02 - present

Member, Multidisciplinary Team Evaluating Medication Errors - UNC School of Medicine, 10/02 – 2/03

Director of Urologic Resident Education - UNC School of Medicine, 1/01 – present

Member, Operating Room Advisory Committee, UNC School of Medicine, 1/01 - present

Unit Chief, Urology Inpatient Service - UNC School of Medicine, 12/00 – present

Co-director, Multidisciplinary Clinic in Genitourinary Oncology - UNC School of Medicine, 0/00 – present

Team leader, Clinical Research Team, Division of Urology - UNC School of Medicine, 8/00 – present

Member, Lineberger Comprehensive Cancer Center - UNC School of Medicine, 7/00 – present

Member, Protocol Review Committee, Lineberger Comprehensive Cancer Center - UNC School of Medicine, 7/00 – 06/08.

Member, Surgical Endoscopy Committee, UNC School of Medicine, 7/00 – present

Member, Laparoscopic Institute of North Carolina, UNC School of Medicine, 7/00 – present

Lecturer - medical students, urology residents on urologic surgery, retroperitoneal/pelvic anatomy (UNC School of Medicine, 4/00 – present); (LSU School of Medicine, 7/99 – 4/00)

Attending - urology clinical service (UNC School of Medicine, 4/00 – present); (LSU School of Medicine, 7/99 – 4/00)

Leadership Courses

Career Development Conversations
Leadership Development Learning Sessions
George Watts Alumni Center
Carolina Club
Chapel Hill, North Carolina
February 1, 2011

Leadership Development for Physicians in Academic Health Centers
Harvard School of Public Health
Center for Continuing Professional Education
Boston, Massachusetts
10/17 – 10/29/2010